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I) ABSTRACT (ENGLISH) 
 
Cellular “failsafe” programs like apoptosis or senescence are genetically encoded, 
stress-responsive mechanisms that ultimately counteract malignant transformation. 
Acute induction of oncogenic Ras provokes cellular senescence that involves the 
p16/Retinoblastoma (Rb) pathway to induce a permanent arrest, but the tumor 
suppressive mechanism in vivo still remains questionable. Senescent cells display 
heterochromatic features on S-phase relevant genes involving methylation of histone 
H3 on lysine 9 (H3K9me), which may depend on the Rb-associated histone 
methyltransferase Suv39h1. 
 
In the present thesis it was shown that Eµ-N-Ras transgenic mice harboring targeted 
heterozygous lesions at the Suv39h1, or the p53 locus for comparison, succumb to 
invasive T cell lymphomas that lack expression of Suv39h1 or p53, respectively. By 
contrast, most N-Ras-transgenic wildtype (“control”) animals develop a non-lymphoid 
neoplasia significantly later. Proliferation of primary lymphocytes is directly stalled by 
a Suv39h1-dependent, H3K9me-related senescent growth arrest in response to 
oncogenic Ras, thereby cancelling lymphomagenesis at an initial step. Suv39h1-
deficient lymphoma cells grow rapidly but, unlike p53-deficient cells, remain highly 
susceptible to adriamycin-induced apoptosis. In contrast, only control, but not 
Suv39h1-deficient or p53-deficient lymphomas senesce after drug therapy when 
apoptosis is blocked. 
 
These results identify H3K9me-mediated senescence as a novel Suv39h1-
dependent tumour suppressor mechanism whose inactivation permits the formation 
of aggressive but apoptosis-competent lymphomas in response to oncogenic Ras. 
  
Keywords:  






II) ZUSAMMENFASSUNG (DEUTSCH) 
 
Apoptose und Seneszenz sind stress-responsive, genetisch verankerte „Failsafe“- 
Mechanismen, welche die Zelle vor maligner Transformation schützen. Onkogenes 
Ras induziert zelluläre Seneszenz über den p16/Retinoblastoma (Rb)-Signalweg und 
führt dabei zu einem permanenten Zellzyklusarrest - das tumorsuppressive Potential 
von Seneszenz in vivo bleibt jedoch bis heute fraglich. In seneszenten Zellen ist die 
Expression von S-Phase relevanten Gene durch die lokale Ausbildung von 
Heterochromatin, bzw. der Methylierung von Histon H3 an Lysin 9 (H3K9me) 
blockiert. Dies lässt vermuten, dass Seneszenz ein epigenetische kontrollierter 
Prozess ist und von Proteinen wie der Rb-assozierte Histonmethyltransferase 
Suv39h1 reguliert wird.  
 
In der vorliegenden Arbeit konnte gezeigt werden, dass Eµ-N-Ras transgene Mäuse 
mit heterozygoten Läsionen im Suv39h1 oder p53 Lokus aggressive T-Zell 
Lymphome entwickeln, die gegen Suv39h1, bzw. p53-Expression selektieren. Im 
Gegensatz dazu entwickeln N-Ras-transgene Wildtyp-Tiere („Kontrollen“) vorrangig 
nicht-lymphoide Tumoren und sterben signifikant später. In primären Lymphozyten 
induziert onkogenes Ras einen Suv39h1-abhängigen, H3K9me-assoziierten 
Proliferationsarrest und kann dadurch Lymphomgenese verhindern. Suv39h1-
defiziente Lymphomzellen wachsen exponentiell und sind, entgegen p53 defizienten 
Zellen, sensitiv gegenüber Adriamycin-induzierten Zelltod (Apoptose). Jedoch 
arretieren nur Kontroll-Lymphome unter Therapie in vitro wenn Apoptose blockiert ist, 
nicht aber Suv39h1 oder p53-defiziente Lymphomzellen. 
 
Diese Resultate identifizieren Ras-induzierte Seneszenz als einen neuen, H3K9me-
abhängigen Tumorsuppressor-Mechanismus, wobei dessen Inaktivierung die 











Cancer is a disease based on intrinsic (epi-) genetic changes that support 
uncontrolled cell proliferation. To counteract unrestrained growth, cells adopt cellular 
“failsafe mechanisms” that eliminate tumor-prone cells by triggering apoptotic cell 
death or a permanent growth arrest.  
Cellular senescence is known as a permanent cell cycle block that limits the 
replicative potential of a cell and holds it in an irreversible G1 arrest. It occurs not 
only as a response to excessive telomere shortening, but also acutely after exposure 
to cellular stresses like oncogenic signaling, oxidative lesions, or chemotherapy.  
Oncogene-evoked senescence mediated by permanent Ras signaling requires the 
tumor suppressor protein p53 and/or the INK4aArf gene products to irreversibly 
arrest a cell in the G1 phase of the cycle. Consequently, the disruption of those 
regulators cancels the failsafe machinery and promotes Ras-driven transformation in 
vitro. Ras-induced senescence was shown to involve epigenetic changes that silence 
S phase promoting genes by Rb-dependent heterochromatin formation, 
accompanied with methylated lysine 9 on histone H3 (H3K9) and the subsequent 
recruitment of heterochromatin proteins such as HP1. This suggests that epigenetic 
factors, e.g. the Rb-bound histone methyltransferase Suv39h1, are crucial mediators 
of the senescence response machinery; and deregulation might impact malignant 
transformation, likely also in vivo.  
Understanding the molecular network of uncontrolled proliferation as a key 
prerequisite of cancer formation has become an issue of intense research and will 
provide not only deeper insights into the process of tumorigenesis, but will also raise 
the possibility of developing more effective and specific strategies to treat cancer.  
 
 
1.1 Cellular senescence and tumor development 
 
 
Cancer arises as a consequence of cells escaping restrictions that normally limit their 
uncontrolled expansion. Suppression and elimination of such autonomous cells or 
their pre-neoplastic precursors are a key property to protect cellular integrity of an 
organism1. Numerous mechanisms, so-called “failsafe programs”, exist in a cell that 
counteract malignant conversion2.  
Apoptosis is the most prominent failsafe mechanism studied so far. In the past 
decades, various publications uncovered apoptosis as the ultimate rescue from 
cellular transformation and as the major response to chemotherapy in cancer patients 
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(reviewed in 3-5). However, it becomes more and more clear that there are additional 
programs that presumably control those biological processes. Certain cellular 
stresses or activated oncogenes do not necessarily force cells to die in a 
programmed fashion, but rather to exit the cycle and enter a permanent arrest 
reminiscent of cellular senescence.  
 
 
1.1.1 Cellular senescence 
 
Decades ago, Hayflick and colleagues invented the term “cellular senescence” as a 
stable proliferation arrest of human diploid fibroblasts in culture when cells loose their 
ability to divide caused by the accumulation of cell doublings6. Later, excessive 
telomere shortening was found to be the initiating event leading to the permanent 
arrest (“replicative senescence”)6,7, linking the phenomenon to the “growing old” or 
“aging” of a cell (Figure 1; left). Indeed, senescent cells were reported to accumulate 
in aging skin fibroblasts of primates8,9 or in other tissues such as liver or retina10,11, 
assuming a putative role for senescence in organismic aging. 
In the past years, also intrinsic factors or environmental insults were found to 
irreversibly block the growth of a cell. Various stimuli like supraphysiological 
mitogenic signaling, DNA damage or oxidative lesions as well as genetic defects are 
known to induce this acute form of arrest (“premature senescence”)12-16 (Figure 1; 
left).   
 
Features of cellular senescence  
 
Senescence depends on several pathways that result in a permanent growth arrest 
irreversibly locking the cell in the G1-phase of the cycle17. Notably, this senescent 
arrest differs from a cell cycle arrest in normal, regenerative tissues. In general, 
oscillating cells in G1 can, before commitment to DNA replication, enter a resting 
state where they survive for extensive periods of time. Importantly, those cells are 
capable to re-entering the cycle upon stimulation, whereas a senescent cell remains 
insensitive to mitogenic signals. 
Although senescent cells are viable and remain metabolically active they undergo 
characteristic changes in morphology turning more flattened and displaying a vacuole 
rich cytpoplasm9. Furthermore, they show an altered gene and protein expression 
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pattern compared to normal cycling or quiescent cells9,18. Upregulation of proteins 
like p5315,19, ARF20,21, p16INK4a15 or the product of the promyelocytic leukemia gene 
(PML)22,23 are main features of a senescent cell (Figure 1; right). In addition, 
lysosomal activity of the cytoplasmic ß-galactosidase enzyme is increased, which can 
be detected by a colorimetric assay using X-gal as substrate – currently the gold 
standard procedure to detect a senescent phenotype9 (Figure 1; picture).  
 
 
Figure 1: Cellular senescence. Left side: Cellular senescence is induced by excessive telomere 
shortening (“replicative senescence”, top) when cells age or acutely as a failsafe program induced by 
activated oncogenes, stress like serum starvation, reactive oxygen species (ROS) or chemotherapy 
(“premature senescence”; bottom). Right side: Features of a senescent phenotype. Picture: 
Chemotherapy induces senescence in apoptotically blocked T cell lymphomas. Endogenous ß-
galactosidase is increased in senescent cells and can be detected by an enzymatic reaction resulting 
in a cytoplasmic, blue staining (own data). 
 
Regulators of cellular senescence  
 
Since senescence is characterized by a permanent G1 arrest17, significant emphasis 
has been placed on proteins that control cell cycle progression and therefore a 
senescent phenotype. Indeed, several cell cycle regulators and their connected 
pathways were shown to mediate a senescence response.  
The CDK inhibitor p16INK4a is a critical effector of G1-/S phase transition and was 
found to be transcriptionally overexpressed during replicative as well as premature 
senescence15,24,25. p16INK4a promotes a G1 arrest by blocking cyclins that are relevant 
for S phase entry (CDK4/6) by maintaining the Rb protein in its hypophosphorylated, 
growth-suppressive state. In this activated form Rb associates with several 
transcription factors, of which the most prominent is E2F, and silences their 
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transcriptional function on S phase relevant promoters (e.g. cyclin E or A). In 
addition, also the transcriptional activity of the tumor suppressor p53 significantly 
increases with the accumulation of cell doublings and upon certain stress stimuli15,26. 
p53 is an essential effector of the cell cycle machinery and induces a broad variety of 
downstream targets (e.g. the CDK inhibitor p21CIP) that contribute to diverse 
phenotypes, including a senescent cell cycle arrest. p53 is regulated by the alternate 
reading frame product of the INK4aArf locus (“ARF”) that blocks the p53-degrading 
activity of MDM2 and therefore stabilizes p53. Importantly, also ARF turns to be 
overexpressed – at least in murine cells – during cellular senescence21,27. 
Taken together, the activation of the p16INK4a/Rb axis and/or the ARF/p5328 pathway 
promotes the establishment of a stable growth arrest and therefore a senescent 
phenotype depending on the cell type and the particular stimulus. 
 
Ras, an oncogene that induces senescence 
 
In additional to numerous stimuli like telomere attrition, DNA damage and some 
chemotherapeutic agents, also oncogenes were shown to induce a senescence-like 
cell cycle block.  
In 1997, Serrano and colleagues unveiled for the first time in rodent and human 
fibroblasts that acute overexpression of oncogenic Ras provokes a cell cycle arrest 
reminiscent of cellular senescence in vitro15. Moreover, Serrano et al found an 
upregulation of proteins like p16INK4a, p53 and p21CIP, a manifest cell cycle block 
locking the cells in G1 and an increase in endogenous ß-galactosidase. This hallmark 
finding underlines the putative senescent phenotype and states that in response to 
oncogenic Ras-signaling cells acutely undergo senescence to counteract 
uncontrolled growth. Data from intense research unveils that Ras predominantly 
involves the MEK/MAP kinase pathway29 that activates the p16-Rb axis to induce 
cellular senescence. Hereby, transcription factors from the Ets family were shown to 
activate the expression of the tumor suppressor protein p16INK4a. As discussed 
above, p16INK4a indirectly promotes the hypophosphorylation of the Rb protein by 
inhibiting the D-type cyclin-dependent kinases CDK4 and CDK6. This keeps the 
transcription factor E2F bound to the Rb protein, halts the cell in the G1-phase and 
prevents S phase entry (Figure 2 and Figure 4).  
In contrast to a “conventional” cell cycle arrest on the Rb-governed restriction point, 
e.g. after serum starvation, the Rb-dependent G1 block representative for 
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senescence is irreversible and cells are insensitive to any mitogenic stimuli. In this 
context, it is highly indicative that E2F responsive S phase genes are stably silenced 
during cellular senescence, likely via local chromatin changes. Indeed, it was shown 
recently that Ras-induced senescent cells display Rb-mediated “senescent-
associated-heterochromatin foci” (SAHFs), transcriptionally silenced heterochromatin 
regions mapped to E2F responsive promoters and enriched for methylated histone 
H3 lysine 9 (H3K9)30. This supports the hypothesis that senescence is an 
epigenetically controlled program where S phase promoting genes are repressed by 




Figure 2: Cellular responses to oncogenic Ras signaling: Excessive mitogenic signaling by 
oncogenic Ras (red) activates the MAPK pathway that leads to the expression of the tumor suppressor 
p16INK4a. p16INK4a blocks the hyperphosphorylation of Rb by inhibitory binding to the kinase domain of 
CDK4/6. This keeps E2F transcription factors bound to Rb, while, consequently, S phase relevant 
genes remain unaffected provoking a permanent cell cycle stop.  
 
 
1.1.2 Cellular failsafe programs  
 
Oncogenes and the cellular failsafe machinery 
 
As previously outlined, it seems that in response to oncogenic stress cells are able to 
recruit programs like senescence to ultimately counteract unrestrained proliferation. 
Those so-called “cellular failsafe mechanisms”, like programmed cell death 
(apoptosis) or senescence, can be recruited upon intra- or extracellular stress stimuli 
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to get rid of defective cells2. In fact, also other oncogenic stresses were shown to 
induce this cellular failsafe machinery.  
The proto-oncogene Myc is a transcriptional regulator that transduces a potent 
mitogenic stimulus by positively regulating cell cycle regulators but, concomitantly, 
induces apoptosis in the absence of survival factors31,32. Hereby, Myc activates ARF, 
the “alternative reading frame” product of the INK4aArf locus that directly inhibits the 
p53 repressor MDM2. This leads to the activation of p53 inducing apoptotic cell death 
(Figure 3).  
 
 
Figure 3: Cellular failsafe programs induced by oncogenic activation: Oncogenic Ras or Myc 
provoke either a terminal growth arrest (senescence) or programmed cell death (apoptosis) by the 
activation of the p16INK4a and/or ARF proteins. Ras-induced senescence is controlled via the inhibition 
of the cyclin dependent kinases 4 and 6 (CDK4/6) either through p16INK4a or alternatively through p53-
induced p21. This retains the E2F transcription factor and keeps it bound to Rb, indirectly silencing 
E2F-responsive promoters of growth promoting S-phase genes. Myc induces apoptosis by the 
induction of the ARF protein that blocks the p53 inhibitor MDM2. Subsequently, p53 can be activated 
and induces downstream effector targets that trigger an apoptotic response or a cell cycle arrest.   
 
Furthermore, the adenoviral oncoprotein E1A stimulates prosurvival signaling and 
permits hyperproliferation; however, E1A fails to transform primary cells because of 















The insufficient regulation of such oncogenic signaling, in particular the cancellation 
of those failsafe programs, provides a basis for cells to adopt unrestrained growth 
capabilities and forces malignant transformation.  
 
 
1.1.3 Tumor development  
 
The development and progression of a tumor is a multistep process that requires 
numerous genetic or epigenetic alterations leading to a malignancy34. Various 
regulatory programs and anti-cancer mechanisms need to be disrupted before 
neoplastic transformation can occur. Growth signal independent proliferation, 
unlimited replicative potential and defects in apoptosis as well as sustained 
angiogenesis and metastasis are considered the “Hallmarks of Cancer” and display 
the main features a cell must acquire during tumorigenesis1.  
 
Malignant transformation  
 
It was a paradigm for years that telomerase activity, together with other cooperative 
events, is prerequisite for malignant transformation35-37. However, the first report in 
2002 sufficiently unveiled that simply two oncogenes in combination with p53 
inhibition are enough to transform human cells in vitro and form, when transplanted 
into nude mice, tumors in vivo38. Later, comprehensive data using rodent systems 
showed that telomerase is not absolutely necessary for malignant conversion. For 
instance, the functional disruption of p53 or genetic ablation of the INK4aArf locus 
cooperates with oncogenic Ras to induce malignant transformation. Primary mouse 
embryonic fibroblasts (MEFs) deficient for p53 or INK4aArf can directly be 
transformed in response to oncogenic Ras and show features like anchorage-
independent growth and a refractile morphology15, characteristics of a malignant 
phenotype.  
Indeed, the activation of proto-oncogenes and the disruption of tumor suppressors 
are frequently found as the driving force in human entities. Tumor suppressors like 
the transcriptional regulator p53, the cell cycle mediators Rb and p16INK4a are often 
mutated in human cancers. Accompanied with mutated (e.g. Ras) or amplified 
oncogenes (e.g. Myc) these alterations permit uncontrolled growth and finally lead to 
a full-blown malignancy1.  
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While there are numerous hypotheses discussing what drives tumor formation, it is 
frequently observed that disruption or cancellation of the cellular failsafe machinery 
displays an early event during tumorigenesis initiating a malignant phenotype (Figure 
4)39. Other defects that are acquired during tumorigenesis are considered to be a 





Figure 4: A road to malignant transformation. Loss of tumor suppressors (e.g. p53, ARF, p16, Rb) 
is required to escape oncogene-induced failsafe programs such as apoptosis or senescence. Their 
inactivation provides the basis for malignant transformation and therefore promotes tumor formation. 
 
Ras and its role in tumor formation 
 
Studies including transgenic mouse models and carcinogen-induced Ras-tumors in 
mice suggest a crucial role for oncogenic Ras during tumorigenesis42-51, but the direct 
consequence of Ras mutations in human tumors has not been fully understood so 
far. Currently, there is convincing evidence from in vitro studies that oncogenic Ras 
triggers senescent growth arrest to prevent transformation. Consequently, pre-
neoplastic lesions with defined primary Ras mutations would likely undergo a 
senescent arrest to counteract malignant transformation, while full-blown 
malignancies have escaped the senescent failsafe machinery. However, those issues 
remain elusive until now. 
 
Enhanced mitogenic signaling was frequently linked to constitutively activated Ras52.  
At present, it is known that mutated ras alleles, predominantly codon 12, 13 or 61, 
were found in almost one third of human cancers52. Moreover, many tumors appear 
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to be driven by activated signaling of the Ras cascade due to constitutive oncogenic 
upstream modifications (e.g. the ErbB2 (Her2/neu) receptor activation53) or 
downstream alterations (e.g. constitutive activation of the B-Raf protein). 
 
Ras genes were identified already in the early 1960s as transforming elements of the 
Harvey and Kirsten rat sarcoma virus54,55; however, their oncogenic capacity was first 
linked to human tumors in the mid 80s52,56,57. The mammalian family of ras genes 
consists of three members located on different chromosomes encoding for the 
independent, but structurally highly related proteins H-Ras, K-Ras and N-Ras58,59. 
Hereby, the H- and K-ras genes reflect the cellular counterpart of the viral Harvey 
and Kirsten genes54,55, respectively, while N-Ras is missing a viral counterpart and 
has been found mutated in a human neuroblastoma cell line. Expression patterns of 
the different isoforms are highly variable during embryonic development and also 
differ in adult tissues60-63. Thus, H-Ras is mainly expressed in brain, muscle and skin, 
N-Ras predominantly in thymic glands or testis and K-Ras shows its highest 
expression levels in gut or lung. However, the predicted function in those organs is 
not fully understood until today.  
 
The K-ras gene is mutated in more than 90% of pancreas carcinomas and 50% of 
colorectal tumors. Also lung and bladder, thyroid and ovarian tumors are frequently 
mutated in one of the ras genes. The mutation leads to the constitutive activation of 
the Ras protein by rendering it insensitive to GTPases and confers a permanent 
stimulation of intracellular kinase cascades irrespective of external stimuli. This 
provokes uncontrolled proliferation and degradation of the extracellular matrix and 
involves the expression of cell cycle regulators (e.g. cyclin D1) or matrix 
metalloproteases (e.g. PAI-1) that influence invasiveness and metastasis.  
 
Tumor formation and epigenetics  
 
It is widely believed that the key to all eukaryotic organisms is inherited through the 
genome and that alterations in the DNA code, e.g. mutations in the Ras genes, are 
the basis for malignancies. Whereas deoxyribonuclein acid (DNA) is considered the 
ultimate template of life, it seems that there are mechanisms beyond that regulate 
and transduce genomic information64.  
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In the past few years, one just realized that variations on an epigenetic level can 
potentiate genetic information without affecting DNA sequence. The “Histone code”, 
proposed in the year 2000 by Strahl and Allis65, suggests a striking role for DNA-
packaging proteins (histones) in changing higher order chromatin structures and 
regulating accessibility of genomic information66. Depending on their modification 
status, histones and related proteins display crucial regulators that control 
transcriptional states. Deregulation likely contributes to tumor development since 
mistargeting of these enzymes contributes to altered transcriptional regulation of 
tumor promoting or tumor suppressing genes67. 
 
Given the attractive hypothesis that Ras-induced senescence is an epigenetically 
controlled process30 it is conceivable that epigenetic regulators trigger a senescent 




1.2 Histone methylation and Suv39h1 
 
 
Eukaryotic DNA is folded, twisted and compacted into a complex structure called 
chromatin. Chromatin condensation relies on the organization of nucleosomes, the 
basic repeating unit of the chromatin that consists of double stranded DNA wrapped 
two times around an octamere of the basic core histones H2A, H2B, H3 and H468-71. 
Nucleosomes are connected to linker histones (H1) that compact and twist the 
chromatin fiber and associate with non-histone proteins leading to higher chromatin 
structures.  
Transcriptionally active chromosome regions (euchromatin) can be discriminated 
from inactive parts (heterochromatin) that are highly condensed and contain 
facultatively or constitutively silenced genes. The dynamic change between 
euchromatin and heterochromatin relies on the re-organization of the nucleosomes. 
Remodelling of certain chromosome regions alters the contact between DNA70 and 
the core histone complexes, and controls a variety of DNA-based processes like 




1.2.1 Histone modifications 
 
Changes in chromatin structure include, besides the depositioning of nucleosomes 
(ATP-dependent “nucleosome-sliding”) through co-factors like Swi/Snf or NURD73-75, 
the covalent modification of histone “tails”, the amino-terminus of the core histones 
that protrude from the nucleosome. These post-translational modifications comprising 
phosphorylation, methylation, acetylation or ubiquitinylation are transduced by certain 
enzymes and are highly specific for the amino acid position (Figure 5 top and 72), 
whereas reversibility of such modifications contributes to the highly dynamic “on-off” 
switch in chromatin structure.  
 
Covalent modifications of histone tails 
 
Chromatin changes are regulated by pathways that transfer extrinsic signals or 
internal changes to the nucleus in order to control gene transcription. Accordingly, 
histone modifications represent a molecular fingerprint of a cell depending on the 
biological phenotype (Figure 5 bottom). 
 
In a resting cell, growth promoting stimuli result in a global change the in histone 
modification pattern contributing to a more relaxed chromatin structure on S-phase 
responsive gene loci. This euchromatic structure is mainly characterized by 
hyperacetylated histones and methylation of H3 (K4, K36, K79). Contrarily, arrested, 
non-proliferating cells display mainly heterochromatin structures on growth promoting 
genes that are less acetylated and predominantly methylated at histone 3 (K9, K20, 
K27) or histone 4 (K20)65,76.  
 
Histone acetylation of lysine residues is catalysed by histone acetyltransferases 
(HATs) and reversed by histone deacetylases (HDACs)77,78. Hyperacetylation of 
histone tails neutralizes the basic histone complex and reduces affinity to DNA, 
thereby mainly contributing to transcriptional activation. Specific kinases induce the 
phosphorylation of several histone residues and mediate, like acetylation, gene 
activation by loosening the contact between nucleosomes, DNA and associated 
proteins. Not surprisingly, phosphoacetylated serine 10 on histone H3 is found upon 
mitogenic signaling in nucleosomes of promoter regions of immediate early genes 
like c-jun or c-fos72,78. Both, histone acetylation and phosphorylation contribute 
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predominantly to transcriptional activation and represent highly dynamic 
modifications that instantly can be reversed by enzymes like HDACs or 
phosphatases. 
 
In contrast, methylation of lysine and arginine residues seems to be of a different 
nature. Depending on the site, methylation of histone residues can regulate either 
transcriptional activation or repression. Until recently, methylation seemed to be a 
permanent epigenetic mark. Specifically, lysine 9 methylation on histone H3 plays an 




Figure 5: Covalent modifications on histone tails and their biological responses: Top: Putative 
sites for methylation (red), acetylation (blue), ubiquitinylation (yellow) and phosphorylation (green) on 
the core histones H3, H4, H2A and H2B72. Other modifications like sumoylation or ADP-ribosylation 
and modifications on the N-terminus of the linker histone H1 are neglected in this context. Bottom: 
Enzymes that catalyze covalent histone modifications of specific residues of histone tails and their 
biological function. Histone acetylases and kinases confer predominantly transcriptional activation, 
whereas histone methylation promoted by methyltransferases mediates both silencing and activation 





1.2.1 Histone methylation 
 
Histone methylation was first described in the early 60s, however, the linkage 
between methylation of histones and transcriptional regulation was discovered more 
than 30 years later. During the last years, exciting new research unveiled the 
importance of histone lysine methylation in heterochromatin formation, gene silencing 
and imprinting (reviewed in 79-81) and is even thought to be relevant for the regulation 
of non-histone proteins82. 
 
Histone lysine 9 methylation and gene silencing 
 
Histone lysine methylation appears to be the key mechanism to silence gene 
transcription on an epigenetic level. Methylation comprises residues on histone H3 
(K4, K9, K27, K36), histone H4 (K20)83-86. Lysines can be mono-, di- or tri-
methylated87,88 and the particular degree on the histone tail confers different 
biological outcomes. Of note, lysine methylation depends on the highly selective 
interplay between other covalent modifications on the nucleosomes or the DNA 
template76. Methylated H3K9 for instance directly antagonizes adjacent H3K4 
methylation as well as phosphorylation of serine 10 that would provoke transcriptional 
activation. In addition, histone methylation can directly be linked to the methylation of 
DNA, an alternative way repressing the transcription of certain genes. Since DNA 
methylation itself blocks acetylation of histone residues, a putative feedback loop 
exists that locally enhances repression and forces heterochromatin formation.  
 
Histone methylation and cancer 
 
Given the fundamental impact of epigenetic processes in the regulation of nearly all 
biological processes deregulation of epigenetic mechanisms contribute to 
uncontrolled proliferation and therefore to cancer formation. Intense research in the 
last years unveiled global changes in DNA methylation and histone acetylation as 
prerequisite for cancer formation, while therapeutic drugs to restore a normal 
epigenetic phenotype are currently in pre-clinical studies or already under clinical 
investigation. Conversely, how histone methylation contributes to tumorigenesis is 
poorly understood so far. Mice defective in Riz1, a HMT that methylates H3K9, are 
prone to tumor formation89 and mutations in the PR-domain of the gene were found 
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in human breast cancer, melanomas, lung carcinomas or colorectal tumors90. 
However, detailed evidence supporting this data is missing up to now. 
 
 
1.2.2 The Suv39h HMTs 
 
In the beginning of the 90s, screens for PEV (position effect variegation) in 
Drosophila melanogaster and S. pombe identified a subclass of 40 gene loci referred 
to as the Su(var) (suppressor of variegation) group91,92. Genes of the Su(var) group 
encode numerous histone deacetylases, protein phosphatases and S-adenosyl 
methionine synthetases, but also heterochromatin associated proteins (Suv(var)2-5, 
Su(var)3-7 and Su(var)3-9). Of note, Drosophila Su(var)3-9 as well as the S. pombe 
Crl4 display the most powerful PEV modifiers.  
In 2000, Rea et al identified and isolated for the first time the corresponding human 
(SUV39H1) and murine (Suv39h1) homologues, respectively93. Those enzymes 
turned out to be histone methyltransferases specific for methylating histone H3 at 
position 9 (H3K9). Importantly, the selective methylation of H3K9 catalyzed by 
Su(var) proteins creates a binding site for heterochromatin proteins like HP1 
contributing to the propagation of stable heterochromatic regions and putatively to 
local gene silencing.  
 
Molecular structure and function 
 
Proteins of the SU(VAR)3-9 family members contain two of the most evolutionarily 
conserved chromatin regulating motifs, the N-terminal “chromo” (chromatin 
organization modifier) and the C-terminal “SET” domain (Figure 6) .  
The SET domain was initially named after the three founding members SU(VAR)3-9, 
E(Z) from the polycomb-group and the trithorax-protein TRX and is found in more 
than 140 gene sequences throughout the species. However, there are SET-domain 
harboring proteins with different and even antagonistic functions, and only a few were 
linked with histone methyltransferase activity94,95. To comprise HMT activity, the 
combination of the SET domain with adjacent cystein rich regions is required. This is 
restricted to only a number of SET domain encoding proteins like the SUV39H family 








HP1 HMT activity  
 
Figure 6: Structure of the human SUV39H1 protein: SU(VAR) proteins contain two highly 
conserved elements: the SET domain (black) with adjacent cystein-rich sequences (red) that comprise 
the HMT activity located at the C-terminus of the protein and an N-terminal chromodomain (dark grey) 
for putative binding partners like HP1.  
 
Members of the SU(VAR)3-9 family are highly conserved from yeast to human and 
also the correlated function, gene silencing through histone methylation, seems to be 
evolutionarily preserved. SU(VAR)3-9 proteins have been shown to be restricted to 
modifying histone H3 at lysine 9 by either mono, di- or trimethylation. H3K9 
methylation creates a binding site for heterochromatin proteins like HP1 that 
contributes to the condensation and compaction of chromatin. Furthermore, HP1 
complexes with Suv39h through the chromo-domain and enhances therefore the 




Figure 7: Heterochromatin formation involves the Suv39h1 protein: Suv39h1 locally methylates 
lysine 9 on histone H3 (red). This recruits heterochromatin proteins like HP1 that bind to the 
methylated H3K9 mark as well as to Suv39h1 and stabilize heterochromatic chromatin regions. 
Simultaneously, phosphorylation of serine 10 (green) and acetylation of the H3K9 (blue) is blocked 
that would otherwise confer a relaxed chromatin structure. DNA methyltransferases (DNMTs) such as 
Dnmt3a, also linked to Suv39h1, methylate DNA on CpG islands and facilitate therefore stable 
heterochromatic sites.  
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Interestingly, acetylation of histone H3 (H3K9ac) or phosphorylation of serine 10 
(H3S10ph) via the Ipl1/aurora kinase blocks the transfer of a methyl group to lysine 
993 (Figure 7). These findings underline the interplay and interdependence of 
SU(VAR)3-9-dependent H3K9 methylation and other site-specific histone tail 
modifications like phosphorylation or acetylation. It was also shown that Dnmt1 and 
Dnmt3a, DNA methyltransferases, interact in vivo and in vitro with the SUV39H1 
HMT and thereby facilitate gene silencing. Since DNMTs, like MeCP2, form 
complexes with histone deacetylases (HDACs) as well, a putative feedback loop 
exists that enhances repression by blocking acetylation of histone residues96-99 
(Figure 7).  
 
Two members of this HMT family, human SUV39H1/SUV39H2 and their murine 
homologues Suv39h1/Suv39h2, will be described as selective H3K9 
methyltransferases in more detail. 
Suv39h enzymes were shown to be crucial epigenetic regulators in mammalian 
development100 and were demonstrated to control chromosomal segregation, local 
gene repression and S-phase related gene silencing. Despite knockout mice deficient 
for both Suv39h1 and Suv39h2 are viable, they are born only at sub-Mendelian ratios 
due to an increased rate of prenatal lethality, and are growth retarded at birth and 
during adulthood100. During embryogenesis, Suv39h1 and Suv39h2 are expressed in 
various tissues in an overlapping pattern. In contrast, in adult mice, Suv39h2 was 
found to be mainly expressed in testis101 suggesting an important role for this isoform 
in the male germline. Indeed, male Suv39h double knockouts are infertile and 
spermatogenesis is severely impaired in those animals. Suv39h double null mice are 
prone to tumor development and highly susceptible for B cell lymphomas, potentially 
due to segregation defects in mitosis leading to chromosomally instable 
karyotypes100. Primary mouse embryonic fibroblasts (MEFs) isolated from double 
knockout mice do not show global changes in H3K9 methylation pattern, however 
H3K9 methylation is completely absent in DAPI-enriched heterochromatic regions. 
These observations underline the putative role of the Suv39h HMTs as regulators of 
pericentric heterochromatin regions protecting genomic stability during mammalian 
development. 
As already highlighted, Suv39h proteins interact with a broad variety of chromatin 
associated proteins and histone modifiers underlining their central role in the 
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regulation and maintenance in stable heterochromatin regions. Importantly, it was 
shown that Suv39h1 associates with the tumor suppressor protein Rb on 
euchromatic regions102. Thereby, the Suv39h1/HP1 complex binds 
hypophosphorylated active Rb by parts of its pocket domain and directs methylation 
of histone H3. The Retinoblastoma protein, regulated by the cyclin D-inhibitor 
p16INK4a, controls the repression of S phase relevant genes by locking the 
transcription factor E2F in its inactive state, likely by methylating nucleosomes in the 
vicinity of the responsive promoters through Suv39h1. This indicates that the 
Suv39h1-HP1 complex does not only regulate pericentric chromatin regions, but also 




Figure 8: Suv39h1 and cell cycle regulation: Suv39h1 interacts with Rb in its hypophosphorylated 
and E2F connected form. This suppresses the transcription of S phase relevant genes by local 
induction of heterochromatin catalyzed by methylation of H3K9.  
 
 
1.3 Proposed Model 
 
Cellular failsafe mechanisms activated upon permanent oncogenic signaling account 
for the ultimate rescue from malignant transformation. Oncogenic Ras has been 
shown to provoke a terminal cell cycle arrest (premature senescence) that is 
considered a putative tumor suppressor mechanism in vitro15. Premature senescence 
is accompanied with accumulation of the tumor suppressor p5315 and the cell cycle 
regulator p16NK4a15 that keeps the Retinoblastoma protein in its hypophosphorylated 
form preventing the transcription factor E2F from transactivating growth promoting 
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genes. Remarkably, in senescent cells E2F responsive promoters are 
transcriptionally silenced by the local formation of heterochromatin enriched for 
methylated histone H3K9 (SAHFs)30. This supports the hypothesis that S-phase 
relevant genes are stably repressed upon Ras activation when cells enter a 
senescent cell cycle arrest, while these genes might be regulated on an epigenetic 
level by specific histone modifications. The observation that the Rb-bound histone 
methyltransferase Suv39h1102 methylates H3 lysine 9 close to E2F responsive 
genes103 proposes Suv39h1 as a key candidate executing Ras-induced senescence 
on an epigenetic level (Figure 9). Consequently, disruption of Suv39h1 is a candidate 
moiety that may disable cellular senescence and therefore promote oncogenic 
transformation. Exploring this and testing whether cancellation of cellular senescence 
also plays a role in tumor development in vivo will be addressed in this work.   
    
 
 
Figure 9: Model: Ras-induced senescence is thought to be a Suv39h1 and therefore H3K9me-
controlled mechanism that controls the silencing of E2F responsive promoters by heterochromatin 
formation.   
 
 
1.4 Mouse Models 
 
 
1.4.1 The Eµ-N-Ras transgenic mouse model 
 
In the late 80s, a tremendous effort was undertaken to generate transgenic mice to 
study the role of oncogenes and their particular impact on tumor development. 
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People around S. Cory at the WEHI in Melbourne developed a model for transgenic 
mice constitutively overexpressing a desired oncogene (e.g. Myc or Ras) in the 
hematopoietic compartment by fusing the oncogene to a tissue-specific promoter, the 
immunoglobulin (Ig) heavy chain enhancer Eµ. This promoter normally directs the 
expression of the Ig heavy chain (IgH) in the B-cell lineage suggesting that transgenic 
mice overexpressing the oncogene develop B cell neoplasia or related diseases. 
However, in individual transgenic founder lines, the promoter was also found to be 
transcriptionally active in other cells of the hematopoietic system – e.g. in primary 
thymocytes or in the myeloid lineage, probably due to the integration environment of 
the transgene. The N-Ras transgenic mouse104 was generated by fusing a human 
mutated cDNA sequence of N-Ras (N-RasV12G) to an EµSV vector and selected for 
overexpressed oncogenic Ras in the hematopoietic compartment. Unlike the 
comparable Eµ-myc transgenic mouse that exclusively develops B cell lymphomas, 
Eµ-N-Ras transgenic animals form tumors of monocytic origin (histiocytic sarcomas) 
and sporadically T cell lymphomas.  
 
1.4.2 The Suv39h1 knockout mouse 
 
With the isolation of the first human and murine histone methyltransferases and their 
suggested role in gene regulation it became attractive to knock out Suv39h1 and its 
homologue Suv39h2 in a mouse model93. The Suv39h1 knockout mouse was 
generated in the year 2001 by T. Jenuwein and co-workers in Vienna together with a 
comparable Suv39h2 knockout mouse and an animal that lacks the function of both 
genes100. To obtain mice deficient for the Suv39h1 gene, the murine Suv39h1 locus 
on the X-chromosome was disrupted by homologous recombination replacing the 
chromo-domain with a selectable RSV-Neo-cassette and the bacterial LacZ gene. 
Mice were born at Mendelian ratios, show normal fertility and no impaired viability 
compared to wildtype mice. Approximately 1/3 of the mice either heterozygous or null 
for Suv39h1 were susceptible to B cell lymphoma between 9 and 12 months of age. 
 
1.4.3 The p53 knockout mouse 
 
The p53 knockout mouse was generated by Jacks and Weinberg105 and is not a main 
part of the present thesis. For details see reference.  
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2.1.1 Mouse strains 
 
Mouse      Reference / Genetic background 
 
Eµ-N-Ras transgenic mouse   Haupt et al, Oncogene 1992 
WEHI, Melbourne, Australia 
       C57BL/6 x SJL 
Suv39h1 knockout mouse   Peters et al, Cell 2001 
       IMP, Vienna, Austria 
       C57BL/6 x 129 sv 
p53 knockout mouse    Jacks et al, Current Biology 1994 
Whitehead Institute, Cambridge, USA  
       C57BL/6 
 
 
2.1.2 Bacteria strains 
 
E. coli DH5α Invitrogen 
Genotype: F-ϕ80dlcZΔM15Δ(lacZYA-
argF)U169 deoR, recA1 endA1 








Cell type       Medium  Source 
 
NIH 3T3       DMEM  cell line 
(Adherent mouse embryonic fibroblast cell line, culture medium 
Cytogenetics: hypertriploid karyotype and 3%  
polyploidy; deleted in the Ink4Arf locus) 
ATCC number: CRL-1658 
Phoenix Eco ϕ -      DMEM  cell line 
(Adherent human embryonic kidney cell line  culture medium 
293T, adenovirus-transformed and stably 
transfected with two plasmids encoding  
the MML virus sequences “gag”, “pol”, “env”) 
www.standford.edu/group/nolan.html 
Splenocytes      B cell medium primary 
(Primary murine splenocytes isolated from a   + IL-7 (50 pg/ml) 
spleen of a non-transgenic mouse with   + 20% FCS 
different genetic backgrounds; suspension 
cells, require feeder cell culture) 
T-Lymphoma cells     B cell medium primary 
(Primary murine Ras-driven T-cell lymphoma    
cells of different genetic background isolated  
from the thymus or lymphnode of a terminally  
sick N-Ras transgenic mouse; suspension 
cells, require feeder cell culture) 
 
 
2.1.4 Chemicals and Reagents 
 
Acrylamide/bis     Serva Electrophoresis 
Adriamycin (Doxorubicin)   Sigma 
Agar Agar       Roth 
Agarose         Serva Electrophoresis 
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Ammoniumpersulfate (APS)   Roth 
Ampicillin sodium salt     Roth 
Bradford reagent (RotiQuant)  Roth  
Bromephenolblue powder   Eurobio  
Calciumchloride (CaCl2)     Roth    
Chloroform   Merck 
Chloroquine diphosphate salt   Sigma 
Colcemid KaryoMAX      Gibco Invitrogen 
DAPI        Sigma 
Dextrose (αD(+)Glucose Monohydrate)   Roth   
Diethyl pyrocarbonate (DEPC)    Sigma 
diSodiumhydrogenphosphatedihydrate (Na2HPO4x2H2O) Merck 
dNTPs          Roth 
DTT        Fluka 
Ethanol absolute   Roth  
Ethidium bromide powder     Roth     
Ethylenediaminetetraacetate  (EDTA)   Roth 
Fetal Calf Serum (FCS)     Biochrom Lot 40Q7441K 
Formaldehyde   Roth 
G-50 fine Sephadex, DNA grade   Amersham 
Glacial acetic acid      Merck 
Glucose       Roth 
Glutaraldehyde   Roth 
Glycerin   Merck 
Glycine      Serva Electrophoresis 
HCl   Merck   
HEPES   Roth 
Hexademethrinebromide (Polybrene)    Sigma  
Interleukin 7 (recombinant)   RDI Research diagnostics  
Isopropanol    Merck 
K3-EDTA       Merck 
KHCO3       Merck 
L-Glutamine       Biochrom Lot K0283 
Magnesiumchloride for PCR    Roche Applied Biosystems 
Magnesiumchloride-hexahydrate (MgCl2)  Roth 
Methanol       J.T.Baker 
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Milk powder    Roth 
N,N,N´,N´-Tetramethylethylenediamine (TEMED) Sigma 
N,N-dimethylformamide (DMFO)   Roth 
N,N-dimethylsulfoxide (DMSO)   Roth 
Na-Desoxycholate      Sigma 
NH4Cl        Merck 
Nonident 40 (NP-40)     Merck 
Paraformaldehyde (PFA)   Sigma 
PBS Dulbecco      Biochrom Lot 0699H 
PCR buffer (w or w/o Magnesiumchloride)  Roche Applied Biosystems 
Penicillin-streptomycin     Biochrom Lot A22139120 
Phenol-chloroform isoamylalcohol   Roth 
PMSF        Sigma 
Potassium ferricyanide (K3Fe(CN)6)   Sigma 
Potassium ferrocyanide (K4Fe(CN)6 x 3 H2O)  Sigma 
Potassiumchloride (KCl)     Merck 
Potassiunacetate (KAc)   Roth 
Propidium iodide   Sigma   
Protease inhibitors (Complete protease inhibitor mix) Roche 
Puromycin dihydrochloride   Calbiochem    
SDS (Sodiumdodecylsulfat)    Roth 
Sodium citrate      Sigma 
Sodiumchloride (NaCl)     Merck 
Sodiumfluoride      Sigma 
Sodiumhydroxide (NaOH)   Roth 
Sodiumorthovanadate     Sigma 
ß-Mercaptoethanol       Roth 
Taq polymerase (AmpliTaq)    Roche Applied Biosystems 
Tris(hydroxymethyl)aminomethane   Merck 
Triton X-100       Merck 
TRIZOL reagent   Gibco Invitrogen 
Trypan blue solution   Sigma 
Trypsin-EDTA (to dilute in 1x PBS or dH2O)  Biochrom  
Trypton/Pepton from casein    Roth 
Tween 20     Roth 
VectaShield mounting medium (Hard set)  Vector 
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X-Gal        Roth 
Xylene cyanol      Eurobio 





All restriction enzymes (BglII, EcoRI, BamHI, NcoI and XbaI), corresponding buffers 
and additional reagents (BSA) were obtained from NEB Biolabs. 
 
Proteinase K       Merck  
RNase A       Fluka  





Oligo   Protocol  Sequence   
 
Suv39h1 fwd 1 Genotyping  5´-GTT GAT GCT TCC TGG TGT GTA GG-3´  
Suv39h1 fwd 2 Genotyping  5´-TTT GAG GGG ACG ACG ACA GTA TG-3´  
Suv39h1 rev Genotyping  5´-AAC AGA TGT GGG GTT GGT GGA G-3´ 
p53 fwd 1  Genotyping  5´-TAT ACT CAG AGC CGG CCT-3´ 
p53 fwd 2  Genotyping  5´-ACA GCG TGG TGG TAC CTT AT-3´ 
p53 rev  Genotyping  5´-TCC TCG TGC TTT ACG GTA TC-3´ 
N-Ras fwd  Genotyping  5´-GCC GCA GAC ATG ATA AGA TAC ATT GAT G-3´ 
N-Ras rev  Genotyping  5´-AAA ACC TCC CAC ACC TCC CCC TGA A-3´ 
 
Suv39h1 cDNA cDNA   5´-GAA TAC GTT GTA CAC CTG CGA GTT-3´ 
Suv39h2 cDNA cDNA   5´-TCA CTT TC ATT TAA CA CCA A-3´ 




TBP fwd  RT-PCR  5´-AAC AGC CTT CCA CCT TAT GC-3´ 
TBP rev  RT-PCR, cDNA 5´-CAT GTT CTG GAT CTT GAA GTC-3´ 
Suv39h1 fwd RT-PCR  5´-CGA GTT CTT AAG CAG TTC CAC-3´ 
Suv39h1 rev RT-PCR  5´-TGC AGG TTG GGA TCA CAA CTA TGG-3´ 
Suv39h2 fwd RT-PCR   5´-CTG CCC AGG ATA GCA TG TT-3´ 
Suv39h2 rev RT-PCR  5´-GCT CCG TTT CCT GAC ACT TC-3´ 
p53 seq PCR fwd RT-PCR  5´-CTT ACC AGG GCA ACT ATG GC-3´ 
p53 seq PCR rev RT-PCR  5´-GCT GGT GAT GGG GAC GGG-3´ 
 
p53 seq fwd  Sequencing  5´-GGG CTT CCT GCA GTC TGG-3´ 
p53 seq rev  Sequencing  5´-CGC TCT CTT TGC GCT CCC-3´ 
 
VB10 (136) fwd TCRR-PCR 1st 5´-AAA CTC TGG GCC ACG ATA CT-3´ 
DB1 (332) fwd TCRR-PCR 1st 5´-CAG CCC CTT CAG CAA AGA T-3´ 
DB2 (385) fwd TCRR-PCR 1st 5´-CCA AGT TCC TCC CCT CTT TA -3´ 
JB1 (2464) rev TCRR-PCR 1st 5´-ATG GGA AGG GAC GAC TCT GT-3´ 
JB2 (1774) rev TCRR-PCR 1st 5´-TGA AGT TGA GAG CTG TCT CCT ACT AT-3´ 
 
VB10 (218) fwd TCRR-PCR 2nd 5´-GCA ACT CAT TGT AAA CGA AAC A-3´ 
DB1 (433) fwd TCRR-PCR 2nd 5´-GCA TCT TAC CAC CAC CTT GC-3´ 
DB2 (432) fwd TCRR-PCR 2nd 5´-GCC CCT CTC AGT CAG ACA AA-3´ 
JB1 (2408) rev TCRR-PCR 2nd 5´-CCT AAG TTC CTT TCC AAG ACC AT-3´ 
JB2 (1765) rev TCRR-PCR 2nd 5´-GAG CTG TCT CCT ACT ATC GAT TTC C -3´ 
 
 
2.1.7 Expression vectors for retroviral transduction 
 
Plasmids used in the present study are ecotrophic vectors based on the Moloney 
Murine Leukemia Virus (MMLV) and taken for retroviral transduction of rodent cells. 
The MSCV (Murine Stem Cell Virus) vector contains the packaging sequence (Ψ+), 
the gene of interest in the multiple cloning site (MSC) driven by a PKG 
(Phosphoglycerate kinase) promoter and a selectable marker (e.g. puromycin 




Plasmid    Backbone   Insert  
 
MSCV-H-rasV12-puro  MSCV-puro   human mut HrasV12 fcs 
MSCV-bcl2-puro   MSCV-puro   murine bcl2 fcs 
MSCV-puro    MSCV-puro   - 
 
MSCV-p16-IRES-GFP  MSCV-IRES-GFP  murine p16 fcs 
MSCV-AFR-IRES-GFP  MSCV-IRES-GFP  murine ARF fcs 
MSCV-IRES-GFP   MSCV-IRES-GFP  - 
 
 





Kit     Components  Company  
 
cDNA synthesis 
Reverse Transcription Kit  - 5x first strand buffer Invitrogen 
     - 0.1 M DTT 
     - SuperScriptII RT 
Blood smears 
Hemacolor     - Fixative solution  Merck 
Rapid staining of blood smears - Color reagent red 
     - Color reagent blue 
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Western blot detection system 
 Supersignal West Pico            - Peroxidase solution Pierce          
- Luminol enhancer  
  Solution 
Sequencing PCR reaction 
BigDye Terminator v.1.1    - BigDye mix   Applied Biosystems  
Cycle Sequencing Kit 
 
 
2.1.9 Antibodies  
 
Primary and secondary antibodies used for WB (Western blot) IF 
(Immunofluorescence) and IPT (Immunophenotyping) 
 
Antibody    Host /   used   Dilution Company 
    Conjugate for    
 
Anti-p16INK4a (M-156) rabbit  WB  1:500  Santa Cruz 
Anti-α-tubulin (T5168) mouse WB  1:8000 Sigma 
Anti-ARF (ab80)  rabbit  WB  1:1000 Abcam 
Anti-N-Ras (OP25)  rabbit  WB  1:500  Oncogene 
Anti-rabbit IgG  HRP  WB  1:5000 Amersham 
Anti-mouse IgG  HRP  WB  1:5000 Amersham 
 
Anti-HP1γ (07-332)  rabbit  IF  1:1000 Upstate 
Anti-H3K9me3 (ab8898) rabbit  IF  1:1000 Abcam 
Anti-IgG AlexaFluor594 rabbit  IF  1:2000 Molecular Probes 
 
Anti-CD68   PE  IPT  1:400  Acris 
Anti-CD138, CD19   PE  IPT  1μg/test BD Pharmingen 
CD8, CD45R (B220) PE  IPT  1μg/test BD Pharmingen 
TCRß, CD90.2 (Thy1.2) PE  IPT  1μg/test BD Pharmingen 
CD117(c-kit), NK1.1  PE  IPT  1μg/test BD Pharmingen 
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Anti-CD43, CD86  FITC  IPT  1μg/test BD Pharmingen 
CD11b (Mac1), sIgM FITC  IPT  1μg/test BD Pharmingen 
CD4, CD5, CD3   FITC  IPT  1μg/test BD Pharmingen 





Marker    Name    Company  
 
Protein  
Molecular weight standard  Roti PRESTAINED   Roth 
 
DNA  
Low molecular weight marker pBR Mix 328   ROTH   




2.1.11 Buffers and Solutions 
 
Solutions for DNA preparation   Reagents  
 
DNA lysis buffer     100 mM Tris-HCl, pH 8.5 
            5 mM EDTA 
            0.2 % SDS 
            200 mM NaCl 
            store at RT  
0.1x TE-buffer  0.1 mM EDTA 
  10 mM Tris (pH 7.5) 




Solutions for Immunofluorescence   Reagents 
 
T-PBS   0.2 % Triton X-100 in 1x PBS 
store at RT   
Fixation solution   2 % Paraformaldehyde in 1x PBS 
prepare freshly 
Blocking solution 3 drops normal serum in 10 ml T-PBS 
 prepare freshly 
Normal serum   From Vectastain ABS Kit, Vector  
 
Solutions for Metaphase spreads  Reagents  
 
Fixative solution     Methanol : Glacial acetic acid (3:1) 
       prepare freshly 
 
Solutions for Plasmid Mini-Preparation Reagents  
 
Solution I  50 mM Glucose 
  25 mM Tris pH 8.0 
  10 mM EDTA pH 8.0 
  store at 4°C 
Solution II  0.2 N NaOH 
  0.5 % SDS 
  prepare freshly 
Solution III  25 % 5 M KAc  
  15 % Acetic acid 
  adjust aq dest to 100 ml  
  store at 4°C 
 
Solutions for PCR / RT-PCR    Reagents  
 
6x loading buffer     0.25 % Bromephenol blue 
       0.26 % Xylene cyanol 
       30 % Glycerol in aq dest 
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       store at RT 
50x TAE      242 g Tris base  
       57.1 ml Glacial acetic acid  
       100 ml 0.5 M EDTA (pH 8.0) 
       store at RT 
DEPC water      0.1 % DEPC in aq dest 
       incubate 1 hour at 37°C, autoclave 
       store at RT 
 
Solutions for Retroviral TransductionReagents  
 
2 M CaCl2       5.88 g, ad 20 ml aq dest 
            filter 0.2-µm  
            store at -20°C 
2x HBS (Hepes buffered saline)  280 mM NaCl 
 10 mM KCl 
 1.5 mM Na2HPO4 x 2H2O 
 12 mM Dextrose 
 50 mM HEPES  
           adjust pH to 7.05  
           adjust to 100 ml with aq dest, filter  
           store at -20°C 
100 mM Chloroquine   0.516 g Chloroquine diphosphate  
       ad 10 ml aq dest 
       filter (0.2-µm) 
       store at -20°C 
 
Solutions for SA-ß-gal assay   Reagents  
 
Fixation solution  2 % Paraformaldehyde in 0.25 %  
       Glutaraldehyde in PBS/MgCl2  
       prepare freshly 
PBS/MgCl2   1 mM MgCl2 in 1x PBS 
       store at RT 
Staining solution  9.25 ml PBS / MgCl2 
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       0.5 ml 20x KC solution 
       0.25 ml 40x X-Gal solution 
       prepare freshly 
20x Potassium cyanide (KC) stock  20 mg K3Fe(CN)6 
       1.050 mg K4Fe(CN)6 x 3H2O 
       in 25 ml 1x PBS 
       store at 4°C in the dark 
40x X-Gal solution     40 mg X-Gal per 1 ml of DMFO 
       store at -20°C  
 
Solutions for Sequencing analysis  Reagents 
 
Sephadex ready-to-use  5 g / 70 ml aq dest 
  store at 4°C 
 
Solutions for Western Blot    Reagents 
 
Protein lysis buffer (Lämmli)   1 ml of 0.5 M Tris-HCl, pH 6.8 
            0.8 ml Glycerol 
            1.6 ml of 10% SDS 
            0.4 ml of 14.3M ß-mercaptoethanol 
            3.8 ml aq dest 
            store at RT 
Protein lysis buffer (Triton X-100)  2.5 ml Tris base (pH 7.6) (50 mM) 
            438 mg NaCl (150 mM) 
            500 μl NP-40 (1%) 
            1.25 ml 10% NaDesoxycholat (0.25%) 
            9.2 ml Sodiumorthovanadate (1 mM) 
            21 mg Sodiumfluorid (10 mM) 
            adjust to 50 ml with aq dest 
            + Protease Inhibitors  
            + 1 mM PMSF 




SDS sample buffer    1 ml 0.5 M Tris-HCl (pH 6.8) 
  0.8 ml Glycerol 
  1.6 ml 10% SDS 
  0.4 ml 14.3 M ß-mercaptoethanol 
           0.4 ml of 1 % Bromephenol blue 
           store at -20°C  
0.5 M Tris-HCl pH 6.8  6 g Tris base 
       60 ml dH2O 
    adjust to pH 6.8, adjust with aq dest to  
    100 ml, store at RT 
1.5 M Tris-HCl, pH 8.8  27.23 g Tris base 
       80 ml dH2O 
adjust to pH 8.8, adjust with aq dest to   
100 ml, store at RT 
10x Electrode running buffer (pH 8.3)  30 g Tris base  
       144 g Glycin 
       10 g SDS 
       adjust with aq dest to 1l 
       store at RT     
Anode I buffer  18.15 g Tris base 
       50 ml Methanol 
       adjust 500 ml aq dest 
       store at RT  
Anode II buffer  1.51 g Tris base 
       50 ml Methanol 
       adjust to 500 ml with aq dest 
       store at RT  
Katode buffer  1.51 g Tris base 
       1.44 g Glycin 
       adjust to 500 ml with aq dest 
       store at RT  
10x TBS    100 ml 1 M Tris pH 8.0 
       300 ml 5 M NaCl2 
       store at RT     
1x TBS-Tween (TBS-T)  0.2 % Tween 20 in TBS  
       store at RT 
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Blocking buffer  5 % dry milk in 1x TBS-T 
       prepare freshly or 
       store at 4°C (1 day) 
Washing buffer  0.5 % Dry milk 
       0.2 % Tween 20 
       in 1x TBS 
       store at RT 
 
Standard solutions    Reagents 
  
PBS (Phosphate-buffered-saline)  8 g NaCl (137 mM) 
       0.2 g KCl (2.7 mM)    
       1.44 g Na2HPO4 (10 mM) 
       0.24 g KH2PO4  (2mM) 
       adjust to 800 ml with aq dest 
       set pH 7.4 
       adjust to 1l with aq dest 
       store at RT 
ACK red blood cells lysis buffer  8.29 g NH4Cl (150 mM) 
       1.0 g KHCO3 (1 mM)  
       200 μl 0.5 M EDTA (0.1 mM) 
  adjust to 800 ml with aq dest, adjust to  
pH 7.3, adjust 1 l aq dest, filter sterile 




Cell culture      Medium 
 
DMEM      Dulbecco´s modified Eagle medium 
       + Glucose 4500 mg/L  
       + L-Glutamine  
       + Pyruvate 
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       Gibco Invitrogen  
       store at 4°C 
IMDM       Iscove's modified Eagle's media 
       + L-Glutamine 
       + HEPES 25 mM  
       Gibco Invitrogen 
       store at 4°C 
Culture medium     DMEM 
       + 10% FCS  
       + Penicillin-streptomycin (100 U/ml) 
       store at 4°C 
B cell medium     DMEM + IMDM (1:1) 
       + 10% FCS  
       + Penicillin-streptomycin (100 U/ml) 
       + 4 mM L-Glutamine 
       + 25 μM ß-mercaptoethanol 
       store at 4°C 
Freezing medium     FCS + 10 % DMSO 
       store at 4°C 
 
Bacteria culture     Medium 
 
LB-Medium (Luria-Bertani)   10 g Trypton 
       5 g Yeast Extract 
       10 g NaCl 
       adjust to 1 l with aq dest (pH 7.2-7.5) 
       store at 4°C 
LB-Medium + Ampicillin    50 μg/ml Ampicillin in LB (liquid) 
       100 μg/ml Ampicillin in LB (plates) 
LB-bacteria plates     10 g Trypton 
       5 g Yeast Extract 
       10 g NaCl 
       15 g Agar Agar 
       adjust to 1 l with aq dest (pH 7.2 - 7.5) 





All instrumentation/material not listed in detail is standard lab equipment  
 
Cell culture Equipment    Company  
 
Cell culture dishes, sterile  TPP 
(different sizes) 
Centrifuge tubes, sterile  TPP 
(different sizes) 
Serological pipettes, sterile  Falcon Becton Dickinson 
(different sizes) 
“Mr. Frosty” Freezing box  Nalgene Cryo 1°C Freezing Container 
Neubauer cell-counter chamber  Superior Marienfeld 
(Improved 0.025 mm, Depth 0.1mm) 
Syringes for single-use, sterile - Braun, Omnifix, BS Plastic 
(different sizes)  
Needles for single-use, sterile Neoject 
(different sizes) 
Disposable scalpel for single-use, sterile Feather 
Polystyrene tubes for FACS analysis (5 ml) BD Falcon 
Cryotubes, sterile PK-100 (1.2 ml) Simport Plastics  
Frosted slides (76 x 26 mm) Engelbrecht   
Nylon Mesh (35 μm) Sefar  
Rotilabo Filter sterile (0.45 μM PVDF) Roth 
Rotilabo Filter sterile (0.22 μM PVDF) Roth 
Microscopy Immersion Oil Merck  
  
Mouse dissection Equipment     
 
- Dissecting board and pins, sterilized 
- Scissors and forceps of different sizes and sharpness, sterilized 




Cytospin Equipment    Company   
 
- Centrifuge (Rotina 35R)  Hettich 
- Inserts (1670) and Plastics (1668) Hettich  
 
Western Blot Equipment    Company  
 
Western blot chamber for SDS-PAGE  C.S.B. Scientific CO 
Western blot semidry blotting apparatus BIORAD 
(Transblot Semidry Transfer Cell) 
Whatman paper (3 MM) Schleicher-Schuell 
PVDF membrane (Immobilon-P) Millipore 
X-O-mat films LS  Kodak 
 
Standard Equipment    Company  
 
Centrifuges Eppendorf Centrifuge 5417R 
 Eppendorf Megafuge 1.0 R 
PCR machine Mastercycler Eppendorf  
Photometer Eppendorf BioPhotometer 8.5 mm 
Microscope Zeiss Telaval 31 
Flow cytometry  Becton Dickinson FACSCalibur  
Fluorescence microscope Zeiss Axioplan 
Flow Hood Typ UVF 6.18S BDK 
Incubator Heraeus cytoperm 2  
UV detection system Biometra T13 UV table and BioDoc  











For equipment and solutions not listed in detail see Material section. 
As an additional reference see also Sambrook & Russel:  `Molecular Cloning´Vol 1-3, 
CSHL Press or www.MolecularCloning.com 
 
 
2.2.1 Mouse work and statistics 
 
Transgenic and knockout mice were kept under standardized S2-conditions based on 
the common GV-SOLAS* and FELASA** guidelines. General mouse work like daily 
animal care, breeding and offspring separation was carried out in collaboration with 
the animal facility of the Campus Virchow Hospital, Charité Universitätsmedizin 
Berlin.  
All mouse strains used in this thesis were backcrossed into a C57BL/6 background. 
In order to obtain Ras-transgenic mice with defined genetic lesions, Eµ-N-Ras-
transgenic animals were intercrossed to Suv39h1 knockout and p53 +/- mice, 
respectively. Tagging of the offspring was carried out according to standard protocols 
and the genotype was assessed by locus-specific PCR as described. For detailed 
information about the Eµ-N-Ras-transgenic mouse, Suv39h1 and p53 knockout mice 
see introduction section (1.4), references and commonly available information 
(www.ncbi.nlm.gov).  
Mice were monitored at least twice a week for any sign of sickness or tumor 
development. Time to death was defined as the latency between birth and a terminal 
stage of disease (symptoms like severe weight loss, hyperventilation and palpable 
hepatosplenomegaly) or sudden death. 
 
Statistical comparison of Kaplan-Meier curves is based on the log-rank test. For 
comparisons of means and standard deviations (“s.d.” denoting a significant P-value 
of < 0.05) the unpaired t-test was applied. All error bars represent the “s.d”. 
 
* GV-SOLAS = Society for Laboratory Animals 




2.2.2 Cell culture 
 
2.2.2.1 Thawing of cells 
 
Reagents, solutions and material 
- Frozen cells in -80°C or LiN2 
- Pre-warmed DMEM culture medium or B cell medium 
- Feeder cells (for lymphoma cells or splenocytes) in conditioned B cell medium 
 
Cells were thawed quickly at 37°C (e.g. in a water bath) and transferred dropwise to 
10 ml medium. After centrifugation (1200 rpm, 5´, RT), supernatant was discarded 
and pellet was resuspended in 1 ml medium. Cells were plated in an appropriate cell 
number on culture dishes or feeder cells (see 2.2.2.4).  
 
2.2.2.2 Freezing of cells 
 
Reagents, solutions and material 
- All cell types 
- Freezing medium (4°C) 
- 1x PBS 
- 1x Trypsin 
- DMEM culture medium or B cell medium 
- 1.0 ml cryotubes  
- “Mr. Frosty” freezing box (stepwise cool down of cells; 1°C in 1´) 
 
Adherent cells: 
After medium was removed from the culture plate, cells were washed with 1x PBS, 
detached with 1 ml Trypsin (37°C; 5´) and resuspend in fresh DMEM medium.  
Suspension cells:  
Cells were directly harvested from the culture plate.   
After centrifugation (1200 rpm, 5´, RT), supernatant was removed and pellet was 
resuspended in ice-cold freezing medium (1 ml freezing medium/cryotube/∼1-2x 106 
cells). Cells were immediately transferred to ice and subsequently placed into the 
“Mr. Frosty” box at -80°C (4h). For long term storage, cells were transferred to LiN2. 
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2.2.2.3 Culture of adherent cells: NIH 3T3 and Phoenix cells 
 
Reagents, solutions and material 
- NIH 3T3 fibroblasts or Phoenix cells 
- Pre-warmed DMEM culture medium 
- 1x PBS 
- 1x Trypsin 
 
NIH 3T3 fibroblasts or Phoenix cells were plated in DMEM medium and cultivated 
under standard conditions (37°C, 5% CO2, 95% humidity) until they reached 
confluency. Cells were split by the following procedure: medium was removed and 
cells were washed with 1x PBS. 1 ml of Trypsin was added until cells detached 
(37°C). After resuspending the cells in culture medium, cells were re-seeded in the 
desired density (1:2 – 1:10) onto new cell culture plates containing fresh medium. 
 
2.2.2.4 Preparation of feeder cells 
 
Reagents, solutions and material 
- NIH 3T3 fibroblasts  
- Pre-warmed DMEM culture medium 
- 1x PBS 
- 1x Trypsin 
- Pre-warmed B cell medium 
 
NIH 3T3 fibroblasts were seeded in DMEM culture medium and grown for 1-2 
passages. When they reached 70-80% confluency, cells were irradiated with 20Gy 
(3000rad) and incubated under standard conditions for another 12 hours. Afterwards, 
cells were split according to standard procedures and resuspended in fresh B cell 
medium. Cells were counted by trypan blue exclusion (see 2.2.8.1) and re-seeded at 
a density of 1 x 106 cells for each 10 cm plate. Medium was changed every 2-3 days 
when feeder plates were not used until they got flattened or vacuole rich. Medium 
enriched with growth promoting factors of irradiated 3T3 cells (12 to 24 hours after 
plating feeder cells) was used as “conditioned medium” for lymphoma/splenocyte 
culture (non-conditioned medium will slow down proliferation or arrest primary cells). 
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2.2.2.5 Culture of mouse T lymphoma cells and splenocytes 
 
Experiments rely on good quality of primary cells and therefore on good culture 
conditions. Cells were only used at a viability of more than 50 % and at low passages 
(to prevent selection for clones that have gained mutations by long-term culture).  
 
Reagents, solutions and material 
- Freshly isolated / thawed lymphoma cells (low passage) or splenocytes  
- Feeder cells (irradiated NIH 3T3 feeder layer) in conditioned B cell medium 
- Conditioned B cell medium from feeder cells for media change 
 
Lymphoma cells or splenocytes were plated at a subconfluent density (∼ 70%) on a 
well conditioned 3T3 feeder layer and cultivated under standard conditions (37°C, 5% 
CO2, 95% humidity). Cells were grown until they grew too dense or medium turned 
too acidic. For splitting, about 1/3 of the cell suspension was removed (cultivated on 
new feeder plates with conditioned medium, frozen or discarded) and fresh 
conditioned B cell medium was added. Feeder cell plates were changed after ∼ 1 
week of culture or when feeder turned too old. For this, the plate was gently rinsed to 
remove lymphoma cells sticking on the feeders and suspension was centrifuged at 
1200 rpm for 5´ (RT). A few ml of the supernatant were retained to resuspend the cell 
pellet and cell suspension was subsequently transferred to a new plate of feeders 
with conditioned B cell medium. Splitting was considered as one passage. 
 
 
2.2.3 Dissection of mice 
 
2.2.3.1 Whole body dissection of mice 
 
Reagents, solutions and material 
- Tumor bearing mouse or non-transgenic wildtype mouse 
- Small box with dry ice, filled with a few ml of H2O  
- 70% Ethanol  
- Mouse preparation equipment 
 
 43
After euthanizing the mouse with CO2, animal was rinsed with ethanol and pinned 
down on a dissecting board with the belly facing up. Mouse was opened using an 
inversed “T”-cut: skin anterior to the urethral tract was held with forceps and the skin 
along the ventral midline was cut from the groin to the chin (careful not to damage the 
muscle wall underneath). Next, incision was made down near the knee on both sides 
of the animal and skin was reflected back. Transparent peritoneal wall was cut 
carefully, body cavity was opened up and reflected back to have access to the 
structures underneath. After removing the diaphragm on the bottom of the breast, the 
sternum was opened by lifting it up with forceps and cutting along each side up to the 
girdle to have access to the thoracic organs. For further steps see next sections. 
 
2.2.3.2 Dissection of tumor bearing mice 
 
Reagents, solutions and material 
-  N-Ras transgenic mouse of the respective genotype  
- Small box with dry ice, filled with a few ml of H2O  
- 70% Ethanol 
- Mouse preparation equipment  and equipment for blood smears 
- Cold 1x PBS 
- 4 % Formaldehyde in 1x PBS 
 
Mouse was sacrificed and opened according to the procedure above. Peripheral 
blood for bloodsmears was obtained by cutting a small piece of tail or by intracardial 
aspiration. Before cutting the peritoneum, lymphnodes that are located 
subcutaneously or in the connective tissue between muscles were checked. After 
opening the peritoneum, abdominal organs were checked for any anatomical 
abnormalities (right place of the organ, size and color). To open the sternum, 
diaphragm was punctured and cut along each side up through the cervical girdle, 
avoiding any damage to the thoracic organs underneath. Organs in the thorax were 
checked intensely. If at any time point organs were enlarged or showed abnormal 
features, they were cut with scissors and forceps, released from the connected tissue 
and rinsed in cold 1x PBS. After measuring the size, parts of the organ and the 
mouse body were conserved (2.2.3.4) and single-cell suspensions were prepared for 




2.2.3.3 Preparation of cells of the lymphoid system 
 
Reagents, solutions and material 
- Freshly prepared organs of the respective mouse 
- Mouse preparation equipment 
- Cold 1x PBS 
- Sterile frosted glass slides 
- Sterile nylon mesh (35 μm) 
- ACK red blood cells lysis buffer 
- 25 gauge needle and syringe 
- Anticoagulant (7.5 % K3-EDTA) 
 
Preparation of spleen, thymus or lymphoma cells 
Spleen, thymus or lymphnodes were washed, placed into cold 1x PBS and gently 
minced between two glass slides using the frosted side of the slides. Mixture was 
resuspended by repeated pipetting. To obtain a single-cell suspension, mixture was 
filtered through a sterile membrane and centrifuged at 1200 rpm for 5´ (RT). To get 
rid of red blood cells, pellet was resuspended in 3 ml of ACK lysis buffer and 
incubated at RT for 5´. Before centrifugation (1200 rpm, 5´, RT), 27 ml of B cell 
medium were added for neutralization. Procedure was repeated if red blood cells 
remained. Cells were frozen or immediately used for further experiments. 
Preparation of bone marrow cells 
Hind limbs were prepared by gently preparing the skin and muscles from the hip, leg 
and the area around. Femora and tibiae were separated from the body at the hip joint 
and at the base of the feet. Remaining muscle and connective tissue were removed 
with scissors and limbs were rinsed in cold 1x PBS. Bone marrow cells were 
collected in cold 1x PBS by flushing the tibiae and femora with 1x PBS using a 25 
gauge needle to expel the bone marrow. Procedure was repeated at least five times. 
Mixture was resuspended by repeated pipetting and filtered according to the protocol 
above. Cells were frozen or immediately used for further experiments. 
Preparation of peripheral blood cells 
Peripheral blood was obtained by intracardial aspiration immediately after euthanasia 
of the mouse. To get blood out of the ventricle, a 25 gauge needle was used to 
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puncture the heart through the peritoneum and diaphragm. Blood was aspirated and 
transferred to a reaction tube including 50 μl K3-EDTA to prevent coagulation. After 
centrifugation (1200 rpm, 5´, RT), lysis of red blood cells was performed as described 
above. Cells were frozen or immediately used for further experiments. 
 
2.2.3.4 Conservation of mouse organs 
 
Reagents, solutions and material 
- Mouse organs / tissue / whole body of mouse 
- 4 % Formaldehyde in 1x PBS 
- LiN2 
 
Organs or tissues were fixed in 4 % formaldehyde for 24 hours (RT). After 
transferring them to 1x PBS, fixatives were kept at RT for long-term storage. 
Alternatively, snap frozen samples were prepared by transferring the organ in LiN2 for 
a few minutes. For long-term storage samples were stored at -80°C. 
 
 
2.2.4 Molecular Biology 
 
2.2.4.1 Preparation of genomic DNA 
 
Reagents, solutions and material 
- Mouse tissue / organs / cell pellet etc 
- DNA lysis buffer 
- Proteinase K 
- Phenol-chloroform isoamylalcohol 
- 3M KAc 
- Absolute Ethanol  
- 70% Ethanol 





Tissue or cell pellet was lysed using 450 μl DNA lysis buffer and 50 μl Proteinase K 
(55° over night). After centrifugation (14 000 rpm, 10´, RT), supernatant was 
transferred to a new Eppendorf cup and 500 μl phenol-chloroform mixture were 
added. After vortexing and spinning (14 000 rpm, 10´, RT), supernatant was 
transferred to a new Eppendorf cup. Procedure was repeated once before 
precipitating the DNA by adding 2x vol. of absolute ethanol and 1/10 vol. 3M KAc. 
After incubation at -20°C over night, DNA was centrifuged (14 000 rpm, 20´, 4°C) and 
washed twice with 1 ml of 70% ethanol. Pellet was air-dried until ethanol was 
completely evaporated. DNA was dissolved in 10-100 μl of 0.1x TE-buffer for at least 
24 hours at 4°C. DNA was measured in a Photometer (260/280 nm) using TE-buffer 
as the reference. DNA is pure at a ratio (260/280nm) of < 1.8; higher values result 
from e.g. ethanol. A faster but less pure way omitting the phenol-chloroform step was 
used to purify tail DNA of mice precipitating DNA with isopropanol. 
 
2.2.4.2 Polymerase chain reaction 
 
Reagents, solutions and material 
- Genomic DNA or cDNA (100-500 ng/μl) 
- 10x PCR buffer incl 15 mM MgCl2 or 10x PCR buffer and 25 mM MgCl2 
- dNTP mix (10 mM each) 
- Respective primer (stock 10 μM) 
- Taq Polymerase (5 U/μl) 
- dH2O 
 
A PCR reaction was prepared according to the following protocols (1x): 
 
Mix for genotyping PCR  Suv39h1  p53   N-Ras  
dH2O       15.15μl  15.1μl   18.5 μl 
10x buffer incl MgCl2  2.5 μl   2.0 μl   2.5 μl 
Primer1 fwd    0.8 μl   0.4 μl    1.2 μl  
Primer2 fwd    1.0 μl   0.4 μl   - 
Primer rev    0.3 μl   0.8 μl   1.2 μl  
dNTP     1.0 μl   0.4 μl   0.4 μl 
DMSO    2.5 μl   -   - 
Taq Polymerase   0.5 μl   0.2 μl   0.2 μl  
DNA     1.0 μl   1.0 μl   1.0 μl 
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Mix for Sequencing- / RT-PCR p53 seq  Suv39h1  Suv39h2 
dH2O       38.85 μl  38.1 μl  38.1 μl 
10x buffer w/o MgCl2  5.0 μl   5.0 μl   5.0 μl  
MgCl2     2.0 μl   3.0 μl   3.0 μl 
Primer fwd    1.0 μl   1.0 μl   1.0 μl 
Primer rev    1.0 μl   1.0 μl   1.0 μl 
dNTP     0.4 μl   1.0 μl   1.0 μl 
Taq Polymerase   0.75 μl   0.4 μl   0.4 μl 
RT-first strand product  1.0 μl   2.0 μl   2.0 μl 
 
Cycling conditions were used for amplification of the desired product as follows: 
 
Conditions   Suv39h1 genotyping  p53 genotyping 
1 Denaturation  95°C  5 min   95°C  5 min  
2 Denaturation  95°C  60 sec  95°C  30 sec 
3 Annealing   56°C  60 sec  62°C  60 sec 
4 Elongation  72°C  90 sec  72°C  60 sec 
5 Elongation  72°C  10 min   72°C  5 min  
6 Hold   4°C  ∞   4°C  ∞ 
repeat steps 2-4  34 x     33 x 
 
Conditions   N-Ras genotyping   p53 PCR sequencing 
1 Denaturation  95°C  5 min   95°C  5 min  
2 Denaturation  95°C  60 sec  95°C  45 sec 
3 Annealing   64°C  60 sec  62°C  60 sec 
4 Elongation  72°C  90 sec  72°C  90 sec 
5 Elongation  72°C  5 min   72°C  5 min  
6 Hold   4°C  ∞   4°C  ∞ 
repeat steps 2-4  31 x     37 x 
 
Conditions   Suv39h1 RT-PCR   Suv39h2 RT-PCR 
1 Denaturation  95°C  3 min   95°C  3 min  
2 Denaturation  95°C  60 sec  95°C  30 sec 
3 Annealing   60°C  60 sec  66°C  60 sec 
4 Elongation  72°C  60 sec  72°C  60 sec 
5 Elongation  72°C   5 min   72°C  5 min  
6 Hold   4°C  ∞   4°C  ∞ 
Repeat steps 2-4  34 x     34 x 
 
DNA products were loaded on an agarose gel and run according to the protocol 
above. Bands were visualized using UV light considering the following fragment 
sizes: 
Suv39h1 geno wt 417 bp / mut 588 bp  Suv39h1 RT-PCR 743 bp 
p53 geno  wt 450 bp / mut 600 bp  Suv39h2 RT-PCR 100 bp 
N-Ras geno  Transgene 200 bp    TBP   681 bp 
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2.2.4.3 Agarose gel electrophoresis 
 
Reagents, solutions and material 
- PCR products in 6x DNA loading buffer 
- 1 kb ladder or pBr marker 
- Agarose 
- 1x TAE 
- 1% Ethidium bromide 
- Equipment for gel electrophoresis 
 
Agarose gels were prepared according to the following procedure: agarose was 
dissolved in 1x TAE at the desired concentration and boiled in a microwave until the 
solution looked crystal clear. Ethidium brodmide was added in the appropriate 
concentration. After casting the gel, hardening occurred within 10-15´. Gel chamber 
was filled with 1x TAE and aliquots of the PCR samples including the corresponding 
amount of loading buffer were loaded into the slots. To determine DNA length of the 
fragments, an appropriate standard marker was used. Depending on the size of the 
supposed bands, gel was run 45´ (100-160V). DNA was visualized by UV-light. 
 
2.2.4.4 Preparation of RNA 
 
Reagents, solutions and material 
-   Low passage lymphoma cells (up to 107 cells) 
- TRIZOL reagent 
- Chloroform 
- Isopropanol 
- 75% Ethanol 
- DEPC H2O 
- Photometer 
 
To homogenize tissue or cell fractions, cells were centrifuged at 1200 rpm for 5´ (RT). 
Medium was removed and pellet was resuspended by gently pipetting in 1 ml of 
TRIZOL reagent. After incubation (5´ at RT), 200 μl of chloroform were added to 
separate RNA from proteins and DNA. Suspension was vortexed for 15´´ and 
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incubated 3´ at RT. After centrifugation, (12 000 g for 15´, 4°C), RNA that remains in 
the colorless aqueous phase was transferred to a new tube. To precipitate RNA, 500 
μl of isopropanol were added to the samples, incubated for 10´ at RT and centrifuged 
again at 12 000 g for 15´ (4°C). Supernatant was removed and pellet was washed 
with 1 ml of 75% Ethanol. After centrifugation at 7500 g for 10´ (4°C), supernatant 
was discarded and pellet was air-dried until ethanol was completely evaporated. RNA 
was re-dissolved in DEPC H2O and incubated for 10´ at 55°C before measuring RNA 
in a photometer (260/280nm) using DEPC H2O as a reference. RNA is pure at a 
260/280 ratio of < 1.8. In general, RNA was stored at -20°C and for long-term storage 
at -80°. All buffers, solutions, tips and other equipment were RNase free. In addition, 
only DEPC-treated H2O was used. For RNA of lymphoma cells, only cells after 
passage 2 were taken to avoid contamination with bystander cells. Lymphoma cells 
were plated 2-3 hours on a plate without feeders to exclude feeder cells in the RNA 
prep. 
 
2.2.4.5 cDNA synthesis for RT-PCR or sequencing reactions 
 
Reagents, solutions and material 
- Extracted RNA of lymphoma cells  
- Corresponding primer for cDNA synthesis (2 mole) or Oligo(dT) (500 ng)  
- DEPC dH2O 
- 5x first strand buffer 
- 0.1 M DTT 
- dNTP mix (10 mM each) 
- 1 U RNasin enzyme 
- 200 U SuperScript Reverse Transcriptase 
 
1μg of RNA and 1μl of primer (or Oligo(dT)) were mixed and adjusted with dH2O to 
12μl. Samples were incubated for 10´ at 70°C to destroy RNA secondary structures 
and transferred to ice for cool down (5´). The following mix was prepared for each 
sample: 4μl first strand buffer, each 1μl DTT, dNTPs and RNasin. Mix was incubated 
for 60´ at 42°C, while after 2´ pre-heating 1μl SS-RT was added. Reaction was 




2.2.4.6 Sequencing reactions 
 
Reagents, solutions and material 
- Genomic DNA or cDNA  (500 ng-1μg DNA) 
- Big Dye 
- Specific 3´ and 5´ sequencing primer (10 μM) 
- dH2O 
- Ready-to-use Sephadex (5g/70ml) to prepare G50 columns 
- Sequencing equipment 
 
For the sequencing reaction, the following mix was set up: 0.5–1 μg DNA, 0.4 μl 5´ or 
3´ primer and 4.0 μl Big Dye. Mix was adjusted to 10 μl with dH2O. Samples were 
mixed well before a PCR was run using the following cycling conditions: 
 
Conditions Sequencing 
1 Denaturation  95°C  3 min    
2 Denaturation  95°C  30 sec   
3 Annealing   50°C  15 sec   
4 Elongation  60°C  4 min   Repeat steps 2-4 25x 
 
Subsequently, the PCR product was purified using sepharose-gradient centrifugation. 
For this, 700 μl of ready-to-use Sephadex was loaded into a G50-column and 
centrifuged at 3000 rpm for 2´ (RT). After exchanging the receiver tube, the PCR 
product was loaded onto the Sephadex column and centrifuged at 3000 rpm (2´, RT). 
Purified PCR product was sequenced at the HU Berlin (Department of Genetics). 
 
2.2.4.7 T-cell receptor rearrangement PCR (TCRR-PCR) 
 
Reagents, solutions and material 
- Genomic DNA (100-500 ng/μl) of low-passage lymphoma cells 
- 10x PCR buffer (incl MgCl2) 
- dNTP mix (10 mM each) 
- Primer (200 nM each; 10 µM stock) for the 1st and 2nd PCR, respectively 




A 1st PCR reaction mix was prepared to amplify any rearrangements of the T-cell 
receptor ß-chain including the variable (V), diverse (D) and joining (J) gene regions:  
 
Mix for TCRR-PCR 
dH2O       37.5μl     
10x buffer (incl MgCl2)  5.0 µl 
VB1 fwd, DB1 fwd, DB2  fwd each 1.0 µl 
JB1 rev, JB2 rev   each 1.0 µl 
dNTP     1.0 μl      
Taq Polymerase (1U)  0.2 μl      
DNA     1.0 μl   
 
After vortexing, cycling conditions as outlined below were used to run the 1st PCR. 
For the 2nd PCR reaction a mix according to the 1st approach was set up using the 
corresponding primers and an aliquot (2.0 µl) of the 1st PCR product. After the 2nd 
PCR using the conditions below, the product was loaded onto a 1.5% agarose gel 
and DNA bands were visualized by UV light. 
  
Conditions   1st PCR reaction  2nd PCR reaction 
1 Denaturation  95°C  30 sec 95°C  5 min  
2 Annealing   59°C  4 min     
3 Elongation  72°C  2 min     
4 Denaturation  95°C  10 sec 95°C  10 sec 
5 Annealing   59°C  1 min   61°C  1 min 
6 Elongation  72°C  30 sec 72°C  30 sec 
Repeat steps 4-6   33x    34x 




2.2.5 Protein Biochemistry 
 
2.2.5.1 Western Blot 
 
Western Blotting was performed using a 15 % SDS-PAGE-system and a semi-dry 
blotting technique. 
 
Reagents, solutions and material 
- Cell pellets for protein lysis (freshly prepared or frozen) 
 
 52
- Protein lysis buffer (Triton-X-100) 
- Protease inhibitors 
- Rotimark Bradford Reagent 
- BSA (stock 1 μg/μl in dH2O) 
- Tris-HCl pH 6.8 and pH 8.0 
- dH2O 
- 30% Acrylamide/bis 37 5:1 mixture  
- 20% SDS 
- TEMED and 10% APS 
- Isopropanol 
- Sample buffer (SDS reducing buffer) 
- 10x electrode running buffer 
- Western Blot equipment 
- Low or high molecular weight standards (Roti Prestained Marker) 
- PVDF-membrane (Immobilon-P) 
- Methanol 
- Whatman paper 
- Anode buffer I & II and cathode buffer 
- Semi-dry blotting apparatus 
- 1x TBS-T (TBS-Tween 20) 
- 5 % non-fat milk (in 1x TBS-T) 
- Washing buffer 
- First and corresponding secondary antibody diluted in TBS-T-milk 
- Pierce supersignal detection system (Solution I and II) 
- Kodak X-O-mat films LS 
 
Preparation of a 15 % SDS-PAGE 
Glass plates were cleaned well with Ethanol before they were set in the casting 
apparatus. A 15 % separating gel (10ml) was set up mixing the following solutions: 
• 2.35 ml aq dest 
• 5.0 ml 30% Acrylamide mix 
• 2.5 ml 1.5 M Tris pH 8.8 
• 50 μl 20% SDS 
50 μl APS and 5 μl TEMED were added to the gel mixture, vortexed and casted 
between the spacers of the prepared glass plates. To prevent evaporation, a few 
drops of isopropanol were carefully added on top. Polymerization occurred within 10´. 
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Isopropanol was removed from the separating gel and rinsed with water. Meanwhile, 
a 4 % stacking gel was prepared (5 ml): 
• 3.4 ml aq dest 
• 0.83 ml 30 % Acrylamide mix 
• 0.63 ml 1.5 M Tris pH 8.8 
• 25 μl 20 % SDS 
Again, 50 μl APS and 5 μl TEMED were added to the stacking gel mixture, vortexed 
and pipetted on top of the separating gel. A comb with the desired number of slots 
was inserted. Polymerization occurred within 10´. After removing the comb, slots 
were rinsed with dH2O and the gel was inserted into the gel running box. 
Protein isolation (whole cell protein extracts) 
Cells were washed once in 1x PBS and centrifuged at 1200 rpm for 5´ (RT). Cell 
pellet was resuspended in protein lysis buffer (vol=3x volume of cell pellet) and 
incubated 40´ on ice. To separate cell debris from proteins, lysates were centrifuged 
(14 000 rpm, 20´, 4°C) and supernatant containing the proteins was transferred to a 
new tube. Protein concentration was determined by a standard Bradford assay (see 
next section) and lysates were kept at -20°C or -80°C for long term storage.  
Protein measurement (Bradford´s protein micro assay) 
A ready-to-use Bradford solution was prepared by diluting Bradford reagent 1:4 with 
dH2O using 1 ml per cuvette and sample. A BSA standard curve was set up using the 
following concentrations: no BSA, 1, 2, 4, 6, 8 and 10 μg BSA including 1 μl of the 
protein lysis buffer each (corresponding to the volume of the protein lysate that is 
measured afterwards). To create a standard curve, the absorbance of the individual 
BSA-samples were determined in a photometer at a wavelength of 595 nm against 
the no BSA-control. The curve was depicted in a linear regression (R2 values close 
to 1.0). For the individual protein lysates, each 1 μl was pipetted into 1 ml of the pre-
diluted Bradford solution and measured in accordance to the standard curve.   
Preparation of the protein samples 
Protein samples were thawed on ice. Volume for the desired protein concentration 
was calculated and the respective amount of loading buffer (sample buffer) was 
added before the samples were boiled for 5´ at 95°C. 
Running the gel 
Gel box was filled with 1x electrode buffer. Boiled protein samples were loaded into 
the slots using 15μl of a molecular weight standard (Rotimark Prestained) as a 
marker. Gel was started at a voltage of 70-90 V until dye front reached the front of 
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the separating gel. Gel was run at a voltage of 130-180 V until dye front was close to 
the bottom. After disassembling the gel apparatus, stacking gel was carefully 
removed and separating gel was immediately used for further blotting. 
Semi-dry blotting procedure 
An Immobilon blot membrane and six pieces of Whatman paper were cut in the size 
of the gel and semi-dry blotting chamber was cleaned. Membrane was activated with 
methanol for a few seconds, rinsed with dH2O and soaked in Anode II buffer. A semi-
dry blotting “sandwich” was set up in the following order: 
• 2 Whatman papers soaked in Anode I buffer 
• 1 Whatman paper soaked in Anode II buffer 
• Activated Immobilon blot membrane 
• Gel 
• 3 Whatman papers soaked in Cathode buffer 
Air bubbles were removed and sandwich was blotted for 60´ at 1.2 mA per cm2 gel. 
Afterwards, blotting apparatus was disassembled and membrane was labeled.  
Antibody incubation 
Labeled membrane was blocked for 30´ at RT in blocking solution under gentle 
agitation. Meanwhile, the first antibody was prepared in an appropriate dilution. 
Membrane was incubated either 4 hours (RT) or over night (4°C) under gentle 
agitation. Afterwards, antibody solution was saved (and re-used when stored at 4°C) 
and membrane was washed 3x 5´ in washing buffer. Subsequently, the membrane 
was incubated for 60´ with the corresponding secondary antibody (RT) under gentle 
agitation followed by three washing steps (3x 15´). Next, the two components of the 
Luminol detection kit were diluted 1:1 in the dark and transferred onto the wet 
membrane. After 1-2´ incubation, membrane was wrapped in a transparent cover and 
put into a cassette. Membrane was exposed to an X-O-Mat LS film for 1´-60´, 




Reagents, solutions and material 
- Splenocytes 
- Cytospin equipment 




- Blocking solution (normal serum in T-PBS according to the secondary antibody) 
- Primary antibodies and respective secondary antibody (in blocking solution) 
- VectaShield Mounding medium for fluorescence (hard set) 
 
Cells were harvested at the appropriate time point, centrifuged (1200 rpm, 5´, RT) 
and washed once in 1x PBS. Cell number and viability were assessed by trypan blue 
exclusion (see 2.2.8.1) to adjust cell number to a final concentration of 200 000 cells / 
ml. 500μl were transferred to a slot of the cytospin plastic and centrifuged at 700 rpm 
for 8´ (15°C). Supernatant was carefully removed by aspiration and cells were fixed 
by a freshly prepared fixation solution. After incubation (15´, RT), slides were washed 
three times in 1x PBS and permeabilized in T-PBS for 30´ (RT). Cells were incubated 
in the first antibody over night (4°C). Slides were washed three times in 1x T-PBS 
(5´) and subsequently incubated with the corresponding secondary antibody for 60´ 
(RT). After extensive washing in T-PBS (3x 15´), slides were mounted and 








Reagents, solutions and material 
- Lymphoma cells (low passage) or freshly prepared lymphoid or liver cells  
- Positive and negative control (spleen, thymus or bone marrow of a wt mouse) 
- 1x PBS 
- Desired fluorescence-conjugated FACS antibodies 
- FACS equipment 
 
At least 106 cells (freshly isolated or cultured) as well as the proper antibody-controls 
were centrifuged (1200 rpm, 5´, RT) and washed in 1x PBS. Pellet was resuspended 
in 100 μl 1x PBS including the diluted antibodies and incubated on ice for 30´ in the 
dark. Afterwards, cells were washed in 1x PBS, filtered through a 35 μM nylon mesh 
and transferred to ice for immediate analysis by flow cytometry.  
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2.2.7 Stable transductions 
 
2.2.7.1 Retroviral transduction 
 
Protocol corresponds to the transfection of a 10 cm Phoenix cell plate for the 
collection of 4 x 3 ml of retroviral supernatant for one 10 cm plate of primary cells. For 
more virus protocol was scaled up. 
 
Reagents, solutions and material 
- Low passage Phoenix cells (<20)  
- Low passage lymphoma cells or freshly isolated splenocytes 
- Retroviral plasmid DNA (including an appropriate marker) 
- Ecotrophic helper plasmid DNA 
- dH2O 
- 2M CaCl2 
- 2x HBS pH 7.05 
- Chloroquine (stock 100 mM, final 25 μM) 
- 1x PBS 
- Polybrene (stock 4 mg/ml, final 4 μg/ml), an transduction enhancer 
- Conditioned B cell medium (filtered to prevent contamination with feeder cells) 
-   IL-7 for splenocytes (pre-stimulation with 50pg/ml 2-6 hours before transduction) 
- FACS equipment or puromycin (stock 300 μg/ml, final 2.5 μg/ml) 
 
Calciumphosphate Transfection of Phoenix cells 
Low passage Phoenix cells were grown in a 10 cm plate to a maximal density of 
70%. 20μg retroviral plasmid DNA, 15μg helper plasmid DNA and 62.5μl CaCl2 were 
mixed in a FACS tube and adjusted with sterile water to 500µl. After adding 500μl 2x 
HBS dropwise under constant agitation (air bubbles), DNA precipitation occurred 
within 5´ at RT (mixture gets milky and cloudy). Meanwhile, old medium of Phoenix 
cells was exchanged. Subsequently, 9 ml DMEM medium containing 25 μM 
Chloroquine and the precipitate (1 ml) were added. After 12 hours incubation under 
standard conditions, medium including the precipitate was removed from the Phoenix 
cells. Cells were washed carefully with 1x PBS and 3 ml of conditioned B cell medium 
were added to collect the first virus supernatant after 24 hours. 
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Preparation of retroviral supernatant and transduction procedure 
The first virus supernatant was harvested after 24 hours by aspiration and filtered 
through a 0.45 μm filter. A well growing cell population (lymphoma cells or IL-7 pre-
stimulated splenocytes) at a subconfluent density was pelleted by centrifugation 
(1200 rpm, 5´, RT) and resuspended in the virus supernatant including 4 μg/ml 
Polybrene. New medium (3 ml) was added to the Phoenix cells for the next round of 
transduction. Afterwards, cells were incubated and grown under standard conditions. 
After 8 hours of incubation, the second virus supernatant was harvested according to 
the procedure above, supplemented with Polybrene and added to the lymphoma or 
splenocyte culture. After spinoculation of the plates (1500 rpm, 10´, 32°), cells were 
incubated and grown until the next round of transduction. In addition, new medium (3 
ml) was added to the Phoenix cells for the next round of transduction. The third and 
fourth virus supernatants were collected 12 hours and 8 hours later according to the 
procedure above (see first two rounds of transduction).  
12 hours after the last transduction, medium was removed from the cells by 
centrifugation and cell pellet was resuspended in fresh conditioned B cell medium. 
Lymphomas and splenocytes were grown for approximately 24 hours to allow cells to 
express the gene of interest. For cells transduced with GFP-plasmids, percentage of 
positive cells was determined by flow cytometry (FACS) using a non-transduced 
control. For cells transduced with an antibiotic marker (puromycin), cell population 
was selected with puromycin (3 d) until non-transduced cells were completely dead.  
 
 
2.2.8 Cell Viability, Apoptosis and Senescence 
 
2.2.8.1 Assessment of cell number and cell viability (Trypan blue) 
 
Reagents, solutions and material 
- All cell types 
- Trypan blue solution (diluted in 1x PBS) 
- Neubauer counting chamber 
 
Cells were harvested, centrifuged (1200 rpm, 5´, RT) and cell pellet was 
resuspended in a small volume of 1x PBS (e.g. 100 μl). The trypan blue solution was 
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added 1:1 and cells were incubated for 1´. An aliquot was transferred to the 
Neubauer chamber and checked for equal distribution of the cells in all four big 
quadrants. If more samples were counted, the trypan blue solution was added shortly 
before counting and cells were placed on ice. Dead cells were blue, viable white. 
For viability assessment and cytotoxicity assays 
At least 200 cells were counted in total (dead and alive). Percentage of viability was 
indicated as the ratio of living cells to the whole cell number. 
For total cell number and growth analysis 
All viable cells in 16 quadrants of the big 4-square-field were counted and number of 
living cells in culture was assessed by the following calculation: total number of cells 
alive in 16 quadrants x dilution factor x 105 x ml. 
 
2.2.8.2 In vitro drug cytotoxicity 
 
Reagents, solutions and material 
- Low passage lymphoma cells 
- Conditioned B cell medium 
- Adriamycin ADR (= Doxorubicin, stock diluted in B cell medium, 50 μg/ml) 
- Trypan blue solution (diluted in 1x PBS) 
- Neubauer counting chamber 
 
Lymphoma cells of a well growing population were harvested and a small aliquot was 
taken to check viability. 2x 105 – 3x 105 lymphoma cells were seeded in duplicates 
onto a 12 well plate in fresh conditioned B cell medium without feeder cells. The 
following Adriamycin concentrations were used: 0.5 μl/ml, 0.1 μl/m, 0.05 μl/ml, 0.01 
μl/ml and an untreated control. Cells were incubated for 24 hours under standard 
culture conditions. After centrifugation (1200 rpm, 5´, RT), viability was assessed 
using trypan blue exclusion. Cell viability of the ADR-treated samples was indicated 
by normalization to the untreated control.  
 
2.2.8.3 Growth curve analysis 
 
Reagents, solutions and material 
- Low passage lymphoma cells on feeder cells or splenocytes on feeder cells 
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- Conditioned B cell medium 
- Trypan blue solution (diluted in 1x PBS) 
- Neubauer counting chamber 
 
Equal amounts of lymphoma cells (1x 104) or retrovirally transduced splenocytes (1x 
103) were seeded in well conditioned B cell medium onto a 24- and a 12-well plate, 
respectively. Growth of the cell population was assessed on a daily basis counting 
viability by trypan blue exclusion. To set equal conditions, the same feeder cells and 
the same conditioned medium were used. Cells were plated at a density of ∼ 60-70 % 
and split onto a bigger plate when necessary. 
 
2.2.8.4 Therapy-induced senescence 
 
Reagents, solutions and material 
- Low passage lymphoma cells overexpressing Bcl2  
- Adriamycin ADR (= Doxorubicin, stock diluted in B cell medium, 50 μg/ml) 
 
A lymphoma population retrovirally transduced with Bcl2 was seeded at a low density 
(∼ 60 %) on fresh feeder plates (each individual lymphoma onto two plates). One 
plate was incubated with 0.1 μg/ml Adriamycin for 5 days without changing medium; 
the second plate was kept as untreated control. Cells were harvested after 5 days for 
senescence assays. If feeder cells died or looked flattened and shapeless, lymphoma 
cells were kept in the old medium and transferred onto new feeder plates.  
 
2.2.8.5 SA-ß-galactosidase assay 
 
Reagents, solutions and material 
- Senescent lymphoma cells or splenocytes and their corresponding controls  
- PBS with 1 mM MgCl2 (pH 5.5) 
- Cytospin equipment 
- Freshly prepared fixation solution  
- Staining solution  
- DAPI (1 mg/ml stock solution, final 1 µg/ml) 
- VectaShield Mounting medium for florescence (hard set) 
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Cells were harvested at the indicated time point. After centrifugation (1200 rpm, 5´, 
RT), cells were washed in 1x PBS. Cell number and viability were assessed by 
trypan blue exclusion to adjust the cell number to a final concentration of 200.000 
cells / ml. 500 μl were transferred to a slot of the cytospin insert and centrifuged at 
700 rpm for 8´ (15°C). Supernatant was carefully removed by aspiration. Cells were 
fixed immediately in freshly prepared fixation solution in order to avoid drying of the 
slide. After incubation (15´, RT), fixative was removed and cells were washed twice in 
PBS/MgCl2. Staining solution was added dropwise and slides were incubated in a 
humidified atmosphere at 37°C in the dark (10-16 hours depending on the 
experiment). Afterwards, slides were gently washed with 1x PBS and mounted while 
still wet. Slides were analyzed under the microscope and stored at 4°C. 
 
2.2.8.6 FACS analysis of senescent cells 
 
Reagents, solutions and material 
- Senescent lymphoma cell population and its respective control 
- 1x PBS 
- FACS equipment 
 
A small aliquot (∼ 105) of senescent lymphoma cells were harvested, washed with 1x 
PBS and resuspend in cold 1x PBS. Cell growth and granularity was determined by 
flow cytometry (FSC/SSC) analysis. Senescent cells were viable and bigger 




2.2.9 Chromosomal stability 
 
2.2.9.1 Metaphase spreads 
 
Reagents, solutions and material 
- Lymphoma cells (low passage)  
- Conditioned B cell medium 
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- 200x KaryoMAX Colcemid stock solution (10 µg/ml final concentration) 
- 0.075 M (=0.56 %) KCl solution 
- Fixative solution (methanol / glacial acetic acid) 
- Dry and clean microscope glass slides 
- DAPI (1 mg/ml stock solution, final 1µg/ml) 
- VectaShield Mounting medium for fluorescence (hard set) 
 
Lymphoma cells (∼ 106-107) were grown to approximately 80% confluency. Cells 
were harvested and seeded onto a new plate in conditioned B cell medium 
containing Colcemid. To enrich for metaphases cells were cultured for 120´ under 
standard conditions. After incubation, lymphoma cells were centrifuged (1200 rpm, 
10´, RT) and supernatant was carefully removed. 1 ml supernatant was kept to 
resuspend cell pellet by vortexing. 10 ml of pre-warmed (37°C) KCl solution was 
added dropwise together with 1 ml of fixative to prevent cell clumping. After vortexing, 
cells were incubated for 20´ at 37°C and centrifuged (1200 rpm, 10´, RT). Again, 
supernatant was discarded, cells were resuspended in 1 ml remaining supernatant 
and fixed with 10 ml of warm (RT) fixative solution while vortexing. Afterwards, cells 
were centrifuged (1200 rpm, 10´, RT) and supernatant was carefully removed. 
Fixation step was repeated four times until pellet was brightly white and cells were 
resuspended in ∼ 500 μl fixative solution. Glass slides were positioned on a tray in a 
humidified atmosphere (boiling water) at a 30° angle and a few drops of the cell 
suspension were applied from about 50 cm height onto each slide. Slides were dried 
at RT. Subsequently, slides were stained with a DAPI solution for 2´ and rinsed with 
dH2O. After mounting the slides in DAPI-free mounting solution, at least 50 
metaphase spreads per individual case were analyzed by fluorescence microscopy. 
Metaphase preps were stored in the fixative solution at -20°C or 4°C. 
 
 
2.2.10 Bacteria work 
 
2.2.10.1 Transformation of bacteria 
 
Reagents, solutions and material 
- Competent E. coli (DH5α) 
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- Plasmid DNA (500 ng-1μg) 
- Pre-warmed LB plates (Ampicillin)  
 
Competent bacteria were thawed on ice using 100 μl for each transformation. 
Bacteria were mixed with the desired plasmid DNA and incubated 30´ on ice. 
Bacteria were heat shocked at 42°C for 1´ and immediately transferred to ice (5´). 1 
ml of pre-warmed LB medium w/o Ampicillin was added and bacteria were incubated 
for 60´ at 37°C under gentle agitation. Bacteria were centrifuged (3000 rpm, 5´, RT) 
and pellet was carefully resuspended in ∼50 μl LB. Suspension was plated on LB 
agar plates and incubated over night at 37°C. Colonies were monitored and picked 
within one week when stored at 4°C. 
 
2.2.10.2 Plasmid DNA Mini-Preparation of bacteria cultures 
 
Reagents, solutions and material 
- Bacteria plate from the transformed DH5α with the plasmid of interest 
- Pre-warmed LB medium including Ampicillin (1 μg/ml) 
- Ice-cold Solution I including 100 μg/ml RNase A 
- Freshly prepared solution II 
- Ice-cold Solution III 
- Absolute and 70% Ethanol 
- dH2O 
 
Individual colonies were picked from the bacteria plate and incubated in 2 ml + 
Ampicillin each over night (37°C) with gentle agitation. Bacteria suspension was 
transferred to a new Eppendorf cup, centrifuged at 14 000 rpm (1´, 4°C) and pellet 
was lysed by adding 100 μl ice-cold sol I. Afterwards, 200 μl of freshly prepared sol II 
were added and after gentle inversion incubated on ice for 5´. 150 μl of ice-cold sol III 
were added and bacteria were incubated 20´ on ice. After centrifugation (14.000 rpm, 
10´, 4°C), supernatant was transferred to a new Eppendorf cup and 1 ml of absolute 
ethanol was added to precipitate DNA. After vortexing and centrifugation (14 000 
rpm, 10´, 4°C) the pellet was washed with 1 ml of 70% Ethanol and centrifuged again 
(14 000 rpm, 10´, 4°C). Pellet was air-dried and DNA was dissolved in ∼30 μl dH2O. 
DNA concentration was measured and checked by standard enzyme digestion. 
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2.2.11 Experimental setting 
 
All mouse strains in the present study were backcrossed to a C57BL/6 background 
and used only >  generation F8. 
To assess the role of Suv39h1 in Ras-driven lymphomagenesis, male Eµ-N-Ras-
transgenic mice were intercrossed either to female Suv39h1 +/- or to female p53 +/- 
mice, respectively. Hereby, breeding was set in a 1:2 ratio (male: female) using mice 
between 10 to 20 weeks of age. Females did not exceed more than five pregnancies. 
After birth of the offspring, mice were separated and genotyped using standard 
protocol procedures. Due to the X-linked Suv39h1 locus mice deficient for a 
functional Suv39h1 (hereafter “Suv39h1 -“) are either male Suv39h1 y/- or female 
Suv39h1 -/- (crossing N-Ras Suv39h1 +/- to Suv39h1 +/-). Mice heterozygous for 
Suv39h1 are always female. To monitor time-to-death latencies, transgenic mice of 
the respective genotypes were monitored at least twice a week for any signs of 
sickness like hyperventilation, severe weight loss as well as palpable lymphnodes or 
unusual behavior. At stages of terminal sickness, mice were sacrificed and the 
tumors were prepared as described elsewhere. For further analysis single cell 




Figure 10: Experimental outline.  Mice with different genetic background were monitored for time-to-







Results from collaborations are outlined when discussing the respective data 
 
 
• Immunohistochemistry / Immuncytochemistry (p16, ARF, CD3, CD11b) 
• Ki67 staining 
• Preparation of paraffin-embedded slides (formalin-fixed tissue) 
 
done by Dr. Christoph Loddenkemper and Simone Spieckermann 
 
 
• GFP enrichment assay 
 
done by Dr. Soyoung Lee (main part) 
 
 
• General mouse care and genotyping 
 
















Oncogenic Ras induces a terminal cell cycle arrest (premature senescence) that is 
capable of preventing malignant conversion in vitro15. It involves tumor suppressors 
like p5315, p1615 or the Retinoblastoma protein and changes in higher order 
chromatin structures30. The Rb-bound histone methyltransferase Suv39h1 might 
therefore represent a crucial effector that controls Ras-provoked tumorigenesis, likely 
by mediating cellular senescence. 
The Eµ-N-Ras transgenic mouse provides an in vivo model for hematological 
malignancies that are driven by oncogenic Ras104. Intercrossing a Suv39h1 
knockout mouse100 allowed us to study the impact of Suv39h1 in Ras-induced 
tumorigenesis and to investigate the role of Suv39h1 in regulating premature 








N-Ras transgenic mouse 
 
Expression status of oncogenic Ras in Eµ-N-Ras transgenic mice 
The Eµ-N-Ras transgenic mouse model is characterized by the constitutive 
overexpression of oncogenic Ras in the blood forming compartment. Basis for this 
model is a human N-RasG12D construct linked to the promoter of the immunoglobulin 
heavy chain enhancer “Eµ”. This ensures the permanent expression of oncogenic N-
Ras in the B cell lineage, but also in other cells of the hematopoietic compartment 
like thymocytes or myeloid cells104.  
To validate this model, either Ras-transgenic or non-transgenic mice were compared 
for their expression of human N-Ras in the hematopoietic system. For this, whole cell 
protein lysates of spleen and thymus of either pre-neoplastic N-Ras (n=3) or non-
transgenic wildtype animals (n=3) were prepared and tested in a Western blot 
analysis for N-Ras levels. A representative blot is shown in Figure 11. 
 
The results clearly reveal that human N-Ras is overexpressed in the spleen and 
thymus of Ras-transgenic mice (“N-Ras”), while, contrarily, no endogenous N-Ras 
expression was detectable in the spleen or thymus of the non-transgenic animal 
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(“wildtype”). The findings confirm the proposed genotype and the functionality of the 




Figure 11: N-Ras is overexpressed in lymphoid organs of N-Ras-transgenic mice. Western blot 
analysis of N-Ras transgenic spleen and thymus compared to the respective wildtype organs.  
Lymphoid compartments were isolated from a 10 week old non-transgenic wildtype mouse and a pre-
neoplastic N-Ras mouse of the same age. 80 µg whole cell lysates were loaded on a 15 % SDS-gel 
and the membrane was probed with either an anti-Ras antibody (detecting human N-Ras of 21 kDa 
size; diluted 1:500) or anti-tubulin (detects murine α-tubulin of 50 kDa size; diluted 1:8000). The 
experiment was carried out with three individual animals (n=3). 
 
 
Suv39h1 knockout mouse 
 
Status of Suv39h1 in Suv39h1 knockout animals 
The Suv39h1 knockout mouse is genetically disrupted in the Suv39h1 gene locus 
and therefore lacks the respective histone-methyltransferase activity in all organs and 
tissues100.  
To test for the functional ablation of Suv39h1, protein expression patterns of mice 
with different genetic Suv39h1 background were examined. However, since there are 
currently no antibodies available that recognize murine Suv39h1 and are functional 
(as tested for the present thesis), the Suv39h1 protein status could not be 
determined in those animals.  
Therefore, we switched to a more genetic test system that confirms the successful 
disruption of the Suv39h1 locus.  
X-linked Suv39h1 was targeted using a conventional lacZ-neo approach. According 
to the insertion size of the introduced sequence (bacterial lacZ gene/neo-cassette), a 
PCR specific for the Suv39h1 gene locus was set up that amplifies a mutant fragment 
larger than the normal wildtype product.  
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Using tissue DNA (tail) of Suv39h1 proficient (+/+), heterozygous (+/-) and deficient 
(y/-) animals (n=3 each genotype) the PCR proves that Suv39h1 was successfully 
disrupted on a genetic level (Figure 12; top). Mice wildtype for Suv39h1 (Suv +/+ or 
Suv y/+) display the wildtype band; knockout mice (Suv -/- or Suv y/-) the mutated 
gene segment. In this context, female heterozygous animals (Suv39h1 +/-) show two 




Figure 12: Suv39h1 is genetically disrupted in Suv39h1 k.o. mice. Top Altered Suv39h1 status in 
mice with different Suv39h1 status. DNA of Suv39h1 +/+, +/- and y/- animals (each n=3) were tested in 
an allele-specific PCR to detect either wildtype or mutant Suv39h1 in normal tissue (tail) of the mice. 
Bottom mRNA level in the hematopoietic system of Suv39h1 +/+ or Suv39h1 y/- mice. RNA from 
spleen and thymus was tested in a RT-PCR approach for expression levels of Suv39h1 using TATA-
box-binding protein (TBP) as a housekeeping gene control (n=3 animals each approach). 
 
Moreover, mRNA levels were investigated to determine not only the genetic, but also 
the functional targeting of Suv39h1 in the knockout mouse. With reference to the 
project outline that examines the role of Suv39h1 in Ras-driven lymphomagenesis, 
only organs from the hematopoietic system were tested. RNA of spleen and thymus 
of either Suv39h1 +/+ or y/- animals (n=3) was isolated and gene specific cDNA was 
transcribed to test for the Suv39h1 message in a semi-quantitative RT-PCR 
approach (Figure 12; bottom).    
As expected, in all Suv39h1 y/- mice no Suv39h1 mRNA was detectable in spleen 
and thymus compared to Suv39h1 +/+ control animals using TATA-box-binding 
protein as a reference. This renders the Suv39h1 knockout functionally as “null” and 




Impact of Suv39h1 on differentiation and proliferation of hematopoietic cells 
Suv39h1 knockout mice display normal viability and fertility and do not exhibit any 
apparent immunphenotype or susceptibility to hematological tumors compared to 
wildtype mice100. According to these observations, no significant difference in 
hematopoietic differentiation would be expected. However, for the present study it 
was crucial to investigate in more detail whether loss of Suv39h1 function might 
provoke a pre-neoplastic state by influencing proliferation or differentiation of 
hematopoietic cells.  
 
Accordingly, the differentiation status of several hematopoietic compartments of 
Suv39h1 deficient mice was investigated to address any variation or shift in the 
lymphoid, myeloid or hematopoietic stem cell population compared to Suv39h1 
proficient animals. Therefore, spleen, thymus, peripheral blood and bone marrow 
cells of three individual mice per genotype (Suv39h1 +/+ and Suv39h1 y/-) at the age 
of four months were isolated and tested in a standard immunophenotyping flow 
cytometry approach. Single cell suspensions of the respective organs were double-
stained with matched pairs of FITC or PE-conjugated antibodies recognizing specific 
antigens on lymphocytes (T/B cells), myeloid cells (monocytes/macrophages), 
progenitor cells (hematopoietic stem cells) or others like natural killer cells.  
 
Each individually stained cell population was measured by flow cytometry and the 
viable fraction in the forward side scatter analysis (FSC/SSC) was blotted in a dual-
color dot blot. A detailed summary of the antibodies used is listed in Table 1. FACS 
parameters (detectors & amps for FL1/FL2) and compensation status were set before 
using the respective negative (isotype) and positive control for each antibody. Dot 
blots were gated uniformly using the same quadrant stats for each antibody pair 
distinguishing negative, single and double positive cell populations. For statistical 
evaluation values were calculated in percentage (%). 
 
Representative blots of spleen, thymus, blood and bone marrow in the relevant 
double stainings are pointed out in Figure 13. The comparative overview in the four 
compartments show nearly identical patterns suggesting no overt difference in the 






Figure 13: Suv39h1 does not impact on hematopoietic differentiation. Immunophenotyping 
analysis of the hematopoietic differentiation status in Suv39h1 knockout mice (n=3) and wildtype 
control mice (n=3) matched to the same age of about four months. Spleen, thymus and bone marrow 
were isolated and peripheral blood cells were obtained by intracardial aspiration. Two-color flow 
cytometry was performed using antibodies detecting myeloid or lymphoid markers and markers on 
hematopoietic progenitor cells (1 µg/test). % indicates the average of n=3. For a summary see T1. 
 
The detailed summary (Table 1) considering all individual mice points out the 
variability in percentages for the indicated antibodies. Again, no obvious difference 
was found in the respective compartments in Suv39h1 proficient and deficient 
animals.  
 
This unveils that in mice lacking functional Suv39h1 the susceptibility for 
hematological tumors is not increased and loss of Suv39h1 in a non-transgenic 






Table 1: Summary of hematological differentiation in Suv39h1 proficient and deficient mice. 
The table indicates the percentage of positive cells in the respective compartment outlined in Figure 
14 as followed: “-“ < 0.5%; “(+/-)” 0.5 to < 1.5%; “(+)” 1.5 to < 5%; “+” 5 to < 15%; “++” 15 to < 45%; 
“+++” > 45 %; “(var)” means high variability (at least half of the mean). Top: Calculation for bone 
marrow and thymus using the indicated antibodies Bottom: Calculation for Spleen and peripheral 







3.2 Phenotype of Ras-transgenic mice with different 
Suv39h1 status 
 
3.2.1 Impact of Suv39h1 in Ras-induced tumorigenesis in vivo 
 
Alterations in the Suv39h1 locus accelerate Ras-induced tumorigenesis in vivo 
 
Overall survival: Kaplan-Meier `Time-to-death´ latencies in Ras-transgenic mice 
To assess the role of Suv39h1 in Ras-driven hematological neoplasia, Eµ-N-Ras 
mice were intercrossed with animals harbouring targeted deletions in the Suv39h1 
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locus. The offspring, comprising N-Ras-transgenic Suv39h1 heterozygous (+/-), 
Suv39h1 null (y/- males; -/- females) and Suv39h1 control mice (+/+), was monitored 
for tumor development and sacrificed when a terminal state was reached. “Time-to-
death” latencies were plotted in Kaplan-Meier format to monitor overall survival 
(Figure 14).  
Transgenic mice with no additional lesions in the Suv39h1 locus (N-Ras controls; 
black; n=63) displayed a slow progression of tumor disease while still appearing 
healthy and entered a terminal state at a median age of 235 days. Strikingly and in 
stark contrast to this observation, N-Ras Suv- animals (orange; n=7) lacking 
functional Suv39h1 entered a comparable state significantly earlier at a median age 
of 66 days (P=0.0004). Remarkably, those mice died only a few days after the first 
signs of sickness. Surprisingly, Ras mice harboring only one mutated allele of 
Suv39h1 (Suv39h1+/-; red; n=17) succumbed to a terminal stage nearly at the same 
time as Suv- animals. This already leads to the presumption that defects in the 
Suv39h1 locus accelerate tumorigenesis in N-Ras-transgenic mice, even in a 




Figure 14: Suv39h1 and p53 defects accelerate Ras-driven tumorigenesis. Kaplan-Meier “Time-
to-death” latencies of N-Ras transgenic Suv null (female Suv -/- and male Suv -/y, n=7; red line), 
female Suv +/- (n=17, orange line) and p53 +/- mice (n=19; blue line) and pooled N-Ras wildtype 
controls with no additional genetic lesion (n=63; black line). N-Ras controls (305 days) comprise the 
“late death” group; Suv nulls (66 days), Suv +/- (80 days) and p53 +/- (141 days) make up the “early 




To validate these observations, N-Ras p53 heterozygous animals were generated 
intercrossing N-Ras transgenics with mice harbouring distinct lesions in the p53 
locus. In this model it is likely that p53 defects have an impact on tumor formation 
since p53 plays a crucial role in Ras-driven tumorigenesis in vitro15 as well as in myc-
driven lymphomagenesis in vivo106. The statistics confirm this hypothesis as Ras p53 
+/- mice (blue; n=19) became sick (median time-to-death 141 days) almost as fast as 
animals with lesions in the Suv39h1 locus. As shown in Figure 14, they display 
significant differences in the “time-to-death” latencies (p=0.02) compared to controls. 
Of note, no signs of tumor were observed in non-transgenic animal deficient for 
Suv39h1 or heterozygous for p53 during a time period of more than one year. 
 
Taken together, the results conclude a strong role for Suv39h1 and p53 in N-Ras-
driven tumorigenesis in vivo since defects in those genes markedly show an impact 
on tumor formation in the context of oncogenic Ras. 
 
 
Suv39h1 defects permit aggressive T cell lymphomas in response to oncogenic 
Ras 
  
The overall survival data discussed above shows that impaired Suv39h1 or p53 
function accelerates cancer formation in vivo and underscores a potential role for 
both players in response to activated Ras signaling in the chosen model. 
To phenotypically assess and characterize Ras-induced neoplasia in the different 
genetic backgrounds, tumor bearing animals were sacrificed at time of terminal 
sickness and dissected for any sign of tumor. The respective infiltrated organs or 
conspicuous tissue sections were prepared and used for further analysis. Therefore, 
parts of the organ were fixed for pathological questions and single cell suspensions 
were generated from the remaining tissue. 
Mice that died early, comprising Suv39h1 deficient, p53+/- and - to a small 
percentage - also control animals, were younger than 180 days (< 180 days) and 
grouped into the so-called “early-death-group”. Mice that died later (> 180 days 
after birth) were summarized in the “late-death-group”.  
 
In the following section several questions will be addressed assessing the phenotype 
of N-Ras-driven entities of the early compared to the late death group: Common 
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macropathology, histology and hematological features as well as the 
immunphenotype.  
Experiments with the “early death group” always comprise a representative number 
of all Suv39h1 and/or p53 genotypes; samples from “late death group” include only 
N-Ras control animals. Of note, it should be mentioned that the small fraction of N-
Ras control mice (without any additional genetic lesions) that also succumbed to the 
“early death phenotype” were analysed in the upcoming paragraphs as well. 
 
Macropathology, histology and hematology of Ras-driven neoplasms 
Macropathological assembling revealed that at terminal stages of disease animals of 
the early death group showed heavy splenic and thymic enlargement, while other 
organs like liver seemed to be unaffected. Contrarily, mice from the late death group 
displayed dramatically enlarged livers and spleens, but only rare thymic involvement 




Figure 15: Macropathology and histopathology of Ras-induced tumors. Left: Animals of the early 
and late death group display different macropathological features. Representative photographs of 
spleen, thymus and liver of the late and early death group at the same scale. Normal organs for 
comparison. Note that the thymus is not available in mice older than about 200 days (involution). 
Right: Different phenotypical characteristics in Ras-transgenic mice of different genotype. H&E 
(Hematoxylin/Eosin) staining of representative organs of Ras-transgenic mice. Formalin-fixed thymus, 
spleen, liver and parts of the lung were embedded in paraffin and cut in 7 µm kryosections to stain 
with H&E (Loddenkemper et al). Note that the thymus is not available in mice older than about 200 
days (involution). Arrows indicate representative areas of lymphoblastic infiltration (early death) or 




Furthermore, to address histological features of these organs, formalin-fixed and 
paraffin-embedded sections were stained with hematoxylin/eosine (Loddenkemper et 
al). Results of representative pictures are outlined in Figure 15 (right). 
The staining unveils that mice from the early death group suffer from a massive 
lymphoblastic infiltration in thymus and spleen even in non-lymphoid organs like the 
lung, whereas the liver remains unpathological. In contrast, late death animal display 
infiltrated histiocytic populations in spleen and liver, while non-lymphoid organs were 
only rarely affected.  
 
To determine the hematological status in the periphery, blood smears were 
performed using a drop of blood by intracardial aspiration from mice at stages of 
terminal illness. The staining according to the Wright’s protocol (Figure 16) 
uncovered that the lymphoblastic phenotype of the early death group is accompanied 
by a drastic leukaemic burden visible by an immature blastic population (stained in 
deep purple), whereas blood smears of the late death group are exclusively normal 
and non-pathological.  
Those histological and hematological examinations suggest that defects in the 
Suv39h1 or p53 provoke different tumor phenotypes in response to oncogenic Ras 
and alterations in the respective loci might promote the early-death lymphoblastic 
phenotype. In addition, the results identify the early death phenotype as more 
aggressive underscoring the time-to-death latencies observed in vivo and assume 





Figure 16: Mice of the early death group show a severe leukemic burden. Representative blood 
smears of N-Ras transgenic mice (Wright’s stain). Peripheral blood was obtained from early and late 




Immunophenotype of Ras-induced tumors 
Taken together, previous data show that N-Ras transgenic mice with defects in the 
Suv39h1 or p53 locus succumb to an aggressive lymphoblastic phenotype and die 
significantly earlier compared to N-Ras control mice that suffer at a later timepoint 
from a non-invasive histiocytic-like invasion. 
 
To study the immunophenotype of those entities, single-cell suspensions of freshly 
prepared tissues were stained in a dual-color immunophenotyping approach with a T 
lymphoid marker as well as with a marker detecting antigens on myeloid cells.  
Therefore, thymus preparations of early death mice (5 each genotype) or late death 
liver cell isolates (5 individual samples) were stained with a marker for T cells 
(CD90.2-FITC) and macrophages (CD11b-PE) using the respective fluorescence-
conjugated antibodies. The viable fraction in the forward sidescatter analysis was 
plotted in a dot blot to determine positive and/or negative populations. 
Representative pictures are shown in Figure 18 (left; upper picture).   
The results highlight clear immunophenotypical discrimination between the early and 
the late death group. Cells isolated from early death animals showed a distinct 
positive population for the T cell maker CD90.2, while cell populations from the late 
death group were exclusively positive for the myeloid antigen CD11b and negative for 
the T cell marker.  
 
In addition, immunohistochemistry for T cell and macrophage markers was performed 
to validate the findings above. Formalin-fixed and paraffin-embedded slides of either 
infiltrated lung or liver were stained with an anti-CD3 antibody, a common T cell 
marker, and with an antibody against the myeloid marker CD11b (Loddenkemper et 
al).  
The results (Figure 17; right) confirm the previous immunophenotyping experiments. 
While CD3 staining is positive in the lung sections of early death animals and 
correspond histologically to the infiltrated lymphoblastic population, stainings of the 
lungs of late death animals remain negative. Contrarily, when liver sections of late 
death mice were probed with the myeloid marker CD11b, the histiocytic population 
turned positive, whereas - according to the pathological phenotype – early death liver 






Figure 17: Mice of the early and late death group display different immunological phenotypes. 
Left top: Immunophenotyping analysis of early death tumors (thymus of a N-Ras Suv39h1 deficient 
mouse) versus late death neoplasms (liver of an N-Ras control animal). Two-color flow cytometry of 
the indicated cell populations for myeloid (anti-CD11b-PE) and T cell markers (anti-CD90.2-FITC). 
Left bottom: Immunophenotype of N-Ras controls, Suv nulls and p53 null lymphomas (5 each 
genotype). Two-color flow cytometry using an anti-CD8-PE and CD4-FITC antibody recognizing 
cytotoxic and helper T cells. Similar distribution of the individual lymphomas is discussed in the text. 
Right: In situ immunohistochemistry of early and late organs (liver / lung) from formalin-fixed paraffin-
embedded slides (7 µm) stained for the myeloid marker CD11b and the T cell marker CD3 
(Loddenkemper et al)  
 
This reveals that early death mice develop a clear T cell phenotype in contrast to late 
death animals showing a histiocytic phenotype from macrophage origin.  
 
To characterize the T cell lymphoblastic population of early death mice in more detail, 
all early samples used in the previous approach were stained with a fluorescence-
conjugated antibody recognizing antigens on either T helper cells (CD4-FITC) or 
cytotoxic T cells (CD8-PE). Flow cytometry was performed according to the 
procedure described in the last paragraph. Representative blots are pointed out in 
Figure 17 (left lower picture) and unveil similar distribution patterns of T cell subtypes 
in the different genotypes (see following table).  
Since T cell lymphomas are of different origin throughout the genotypes it seems that 







Taken together, the immunophenotyping revealed that upon oncogenic Ras signaling 
in the hematopoietic system, defects in the Suv39h1 or p53 locus provoke a T 




Tumor characteristics: Proliferation and clonality of early death lymphomas 
Previous experiments showed that in response to oncogenic Ras defects in the 
Suv39h1 or p53 locus permit an aggressive tumor-like phenotype, whereas animals 
without any additional genetic lesion succumb mainly to a milder form of histiocytic-
like disease. However, it needs to be investigated whether the altered Suv39h1 or 
p53 status drives a clonal tumor or simply the hyperproliferation of T cells. Hence, 
growth parameters and clonality were assessed in early death T cell isolates. 
 
To determine growth parameters, paraffin-embedded sections of the spleen derived 
from early death phenotypes were stained with the proliferation marker Ki67 
(Loddenkemper et al). Spleen sections from late death animals were taken as 
controls. Representative pictures are shown in Figure 18; upper part). 
The results of the immunohistochemistry revealed that proliferation is markedly 
increased in all of the early samples. Hereby, 77% (Suv39h1 defective; early control) 
and up to 90% (p53 -/-) were positive for the staining. This underlines the aggressive 
and fast growing T cell lymphoblastic phenotype. Contrarily, in the late death group, 
only 10% turned positive characterizing a less invasive malignancy contributing to a 
longer overall survival of N-Ras control animals.     
 
 
However, in principal, also a non-malignant, benign cell population can proliferate 
due to permanent external growth factor supply or intrinsic stimuli. Those 
hyperproliferating tissues are characterized by a polyclonal cell population. 
Accordingly, it is necessary to test if the T lymphoblastic population is from 
monoclonal origin displaying a tumor entity.  
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Therefore, DNA of the early death group was tested for T cell receptor ß (TCRß) 
rearrangement in a two-step PCR analysis. During T cell maturation in the thymus, 
the TCR is rearranged by V-D-J recombination and in a normal thymus diverse 
variants of the TCRß chains are present. In contrast, a tumor population is derived 
from a clone that expresses only one distinct rearranged TCRß chain. In this 
approach, the rearrangement of the variable region (V) of the TCRß to any diverse 
(D) or joining (J) segment can be detected. A normal thymus population results in 




Figure 18: Tumor characteristics in terminally early death tumors. Top: Proliferation status. 
Formalin-fixed and paraffin-embedded sections (7µm) of the spleen were stained for the Ki67 protein 
of animals of the indicated genotypes (n=3). Quantification values (100 cells) of three individual 
samples of each genotype were averaged (in %) and blotted including standard deviations 
(Loddenkemper et al). Bottom: Clonality of the lymphoblastic T cell population (T-cell receptor ß-
rearrangement). DNA was isolated to determine the V-D-J recombination status in the T cell tumor 
population using a multiplex 2-step PCR protocol. The representative picture includes the individual 
genotypes (control, Suv39h1 heterozygous and null, n=1; p53 heterozygous, n=2) and the positive 





As outlined in Figure 18 (lower part), the polyclonal thymus population of a non-
transgenic wildtype mouse expresses a huge arsenal of different TCRß chains 
(smear), whereas thymus DNA isolated from early death mice results in sharp bands, 
independent of the different genotypes. This argues for a monoclonal population of 
N-Ras early death animals rendering the respective entities as T cell lymphomas.    
 
In summary, these results unveil that in mice with an altered Suv39h1 or p53 status 
oncogenic Ras provokes aggressive tumors from T lymphoid origin which do not 
develop (besides a small fraction) in a N-Ras driven wildtype background. The data 
strongly argue for a crucial role of Suv39h1 and p53 controlling Ras-induced 




3.3 Molecular signature of Suv39h1 deficient lymphomas 
 
 
3.3.1 Oncogenic Ras and the Suv39h1 status 
 
Ras selects against Suv39h1 expression during tumor formation 
 
In the previously described experiments it was shown that altered expression of 
Suv39h1 or p53 accelerate oncogene-driven tumorigenesis in N-Ras transgenic 
mice, likely by disabling a failsafe mechanism that normally protects against Ras-
induced lymphomagenesis. Notably, this was observed not only for N-Ras Suv39h1- 
mice, but also for animals with a heterozygous Suv39h1 +/- background. Since those 
Suv39h1 +/- mice show almost identical time-to-death latencies and do not differ in 
their phenotype it is highly suggestive that Ras may select against Suv39h1 during 
lymphoma formation. Likewise, since functional loss of p53 correlates with 
accelerated tumorigenesis in vivo and in vitro, p53 function might also be lost in N-
Ras transgenic p53 heterozygous animals in this model. 
 
Status of Suv39h1 and p53 in Suv39h1- and p53-deficient lymphomas 
To investigate whether oncogenic N-Ras selects for Suv39h1 or p53, allele-specific 
PCR was performed to detect wildtype and mutant Suv39h1 and p53, respectively. 
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For this, genomic DNA from low-passage lymphoma cells was isolated and set in a 
polymerase chain reaction with the corresponding normal tissue DNA (tail) from the 
mouse. DNA of MEFs (mouse embryonic fibroblasts) was taken as a standard and N-
Ras controls from the early death group served as cell type control. 
 
According to the Knutson’s hypothesis, Ras selected for the remaining wildtype p53 
allele in heterozygous p53 +/- mice during lymphomagenesis, resulting in a “loss of 
heterozygosity” (LOH) in 4/5 lymphoma samples tested (Figure 19 top; picture in the 
middle). These are predicted data since in different already published models a p53 
LOH is detectable in vivo as well as in vitro.  
However, in Suv39h1 heterozygous lymphomas the wildtype allele was still 
detectable (Figure 19; picture in the middle; n=4) on a genomic level. This assumes 
no gross deletions in the Suv39h1 locus during Ras-driven lymphomagenesis. 
Remarkably, when those tumor samples were tested for mRNA expression levels of 
Suv39h1 in an RT-PCR approach, no transcript was detectable in any of the cases 
tested (n=12; Figure 19 top; upper picture). These data suggest that in those animals 
oncogenic Ras likely selects for cells where the remaining Suv39h1 wildtype allele 
maps to the inactivated X-chromosome (Barr-body) and is therefore inactivated 
already before tumor formation. Therefore, former Suv39h1 heterozygous 
lymphomas can be declared functionally as “null” lymphomas.  
 
In line with the previously described observations these data uncover that Ras 
promotes lymphomagenesis by selectively disrupting a functional Suv39h1 message 
or wildtype p53. Accordingly, these players seem to be important mediators of Ras-
induced tumorigenesis, also in vivo.   
 
Further examination was made to investigate if Suv39h1 loss can potentially protect 
p53 LOH during Ras-driven lymphomagenesis.  
Therefore, N-Ras mice heterozygous for p53 (N-Ras 53+/-) were intercrossed with 
Suv39h1 +/- mice in order to obtain N-Ras p53+/- Suv- (2 cases) or N-Ras p53+/- 
Suv+/- (1 case) animals (see scheme Figure 19 bottom; upper picture). 
Subsequently, the offspring was monitored for time-to-death latencies and tested for 
the status of p53 and Suv39h1. N-Ras control lymphomas from the early death group 






Figure 19: Cells select against Suv39h1 or p53 during lymphomagenesis. Top: Status of 
Suv39h1 or p53 in Ras-driven Suv39h1 or p53 heterozygous lymphoma cells. Suv39h1 +/- (n=4; 
upper) or p53 +/- (n=5; middle) lymphomas were tested in an allele-specific PCR to detect the wildtype 
or mutant Suv39h1/p53 allele in tumor (T) or the corresponding normal tissue (N) for comparison. As 
an internal control mouse embryonic fibroblasts of the respective genotype were used. mRNA level in 
Suv39h1 heterozygous lymphoma cells (n=5; lower): RT-PCR for Suv39h1 and TATA-box-binding 
protein (TBP) as a control. Bottom: Breeding scheme (upper; see also text). Suv39h1 RT-PCR 
(middle) and genomic p53 PCR (lower) were preformed as described above. DNA or RNA of 





As expected, all animals succumb to a terminal state of disease at approximately the 
same time as the early death group and showed identical features. T lymphoma cells 
were isolated and tested either in an allele-specific PCR or an RT-PCR approach for 
p53 or Suv39h1, respectively.  
Impressively, data revealed that Ras selected against Suv39h1 since no mRNA 
transcripts were detectable in any lymphoma; however the p53 wildtype was retained 
(Figure 19 bottom; lower picture). According to these results it is highly conceivable 
that in response to oncogenic Ras loss of Suv39h1 protects from co-inactivating p53. 
It seems that selection against Suv39h1 is quite an early event, while a p53 LOH 
occurs later (see time-to-death Kaplan-Meier curves). 
 
Importantly, these data unveil that it is sufficient to block Suv39h1 function to drive 
Ras-induced lymphomagenesis without compromising p53 function in vivo. In 
addition, the results show that control lymphomas from the early death group retain 







3.3.2 Role of Suv39h1 in the Ras-pathway  
 
Suv39h1 acts downstream of p16 
 
Previous experiments showed that Suv39h1 is a crucial mediator of Ras-induced 
tumorigenesis and loss of the histone methyltransferase can even compensate for an 
additional p53 LOH. This places Suv39h1, like p53, as a regulator protein in the Ras-
signaling cascade.  
Latest research revealed the INK4aArf gene products p16 and ARF as important 
players in the Ras-signaling pathway. They are activated in response to oncogenic 
Ras and transfer the signal downstream to the p53 protein. As a consequence, loss 
of p53 leads to the accumulation of p16 and ARF. 
 
To evaluate the role of Suv39h1 in the Ras-signaling cascade upstream or 
downstream of those players, protein expression levels of p16 and ARF were 
determined. In addition, the selective enrichment for those proteins was tested in a 
Suv39h1 proficient and deficient background. p53 null lymphoma cells were taken for 
comparison and N-Ras control lymphomas from the early death group served as cell 
type control. 
 
Suv39h1 null lymphomas tolerate high p16 levels, but select against ARF   
To test for endogenous p16 expression, whole cell protein lysates were isolated from 
low-passage lymphoma cells of the respective genotype and evaluated in a Western 
blot analysis, while endogenous ARF levels were assessed performing 
immunohistochemistry on infiltrated lung sections of terminally sick mice. 
Data in Figure 20 (top) unveil particularly high p16 levels in Ras Suv39h1 null or p53 
lymphomas compared to quite modest expression profiles in control samples. 
Contrarily, in Suv39h1 deficient entities and in controls, ARF levels were almost 
undetectable in paraffin-embedded sections of the lung (Loddenkemper et al). In 
contrast and in line with previously published data, ARF is highly overexpressed in 
p53 nulls (Figure 20; middle). 
 
This already underlines the potential role of p16 acting upstream of Suv39h1 in 
oncogenic Ras-signaling, whereas the ARF protein does not seem to act in the 




Similar results were obtained when p16 and ARF were retrovirally introduced into 
lymphomas of different genetic background and checked for the selective enrichment 
after a distinct time period (Soyoung Lee). For this, control, Suv39h1 or p53 deficient 
cells were retrovirally transduced with either a MSCV-p16-IRES-GFP or a MSCV-
ARF-IRES-GFP construct, set to 10% GFP positivity and monitored for GFP levels 
after 48 hours by flow cytometry.  
The results (Figure 20, middle) support previous findings that Suv39h1 null cells 
tolerate supra-physiological levels of p16 and even enrich for the protein during the 
two days period comparable to p53 deficient lymphomas. In contrast, Ras control 
cells did not enrich for p16 and maintained stable levels after 48 hours arguing for an 
active p16 signaling pathway. On the other hand, high levels of ARF were not 
tolerated in Suv39h1 null cells and lymphomas selected against the protein - like in 
Ras control lymphomas where the GFP fraction decreased after 48 hours. Again, this 
is in line with the Western blot analysis and the immunohistochemistry results. 
 
These results give a deeper insight into the signaling pathways Suv39h1 is involved 
during Ras-induced tumorigenesis in this model – likely acting downstream of p16. 
However, it seems that a functional ARF-p53 axis is retained in Suv39h1 null 






Figure 20: Role of p16 and p19ARF in Suv39h1 null lymphoma.  Top: Western blot analysis of 
Ras-driven lymphoma cells of the indicated genotypes. Whole cell lysates (80 µg) of low-passage 
lymphoma cells were separated with a 15% SDS-PAGE and the membrane probed with an anti-p16 
antibody (1:500) detecting murine p16 (16 kDa) or anti-tubulin (1:8000) of 50 kDa as a loading control. 
Middle: Immunohistochemistry for p19 ARF in Ras-induced lymphomas of the indicated genotypes 
were stained for ARF. Formalin-fixed and paraffin-embedded sections (7 µm) of infiltrated lung were 
probed with an anti-ARF antibody (1:10) (Loddenkemper et al). Bottom: GFP-enrichment assay in 
lymphoma cells of different genotypes. Suv39h1 null (n=8), p53 null (n=3) and control lymphomas 
(n=5) were transduced retrovirally with either a MSCV-p16-IRES-GFP (left) or a MSCV-ARF-IRES-
GFP construct (right). After transduction cell population was set to 10% GFP positivity and measured 




3.4 Molecular defects in Suv39h1 compromised lymphomas  
 
As previously shown, Suv39h1 represents a crucial mediator of Ras-induced tumor 
formation in the Eµ-N-Ras model. Loss of the histone methyltransferase likely 
controls, on the one hand, a mechanism that normally prevents lymphomagenesis or, 
on the other hand, supports secondary defects that promote lymphoma formation.  
 
In the following section, the molecular defects in Suv39h1 deficient cells will be 
addressed and evaluated. In all experiments performed, N-Ras control lymphomas 
from the early death group were taken as cell type control. 
 
 
3.4.1 Ras levels, p53 status and numeric aberrations 
 
Unequal Ras levels, mutated p53 or polyploidy do not drive lymphomagenesis 
in a Suv39h1 null background 
 
Ras protein expression and p53 gene sequencing analysis 
Oncogenic Ras involves the activation of the Raf-MAP-Kinase pathway and the 
upregulation of proteins such as p53 or the INK4aArf gene products. This likely 
enhances the pressure to inactivate one of those key regulators during 
tumorigenesis. Especially p53 as gatekeeper of cell integrity might be mutated in 
Suv39h1 defective lymphomas and contribute to the phenotype. 
 
Hence, evaluation of the p53 status is one crucial aspect that needs to be addressed. 
Therefore, RNA from Suv39h1 null and control lymphomas was isolated and used for 
amplifying p53 specific cDNA for further sequencing of the DNA binding domain 
(exon 4-8), a hotspot region for pointmutations in the p53 gene.  
Representative sequencing analysis is outlined in Figure 21. In all of the samples 
tested (5/5 each genotype) sequencing analysis unveiled wildtype p53 of the DNA 
binding domain. Consequently, this assumes a functional p53 that is active in N-Ras 






N-Ras control: forward p53 seq exon 4-8  
 
 
N-Ras Suv39h1 null: forward p53 seq exon 4-8  
 
 
Figure 21: N-Ras control and Suv39h1 deficient lymphomas retain wildtype p53 exon 4-8. RNA 
of low-passage lymphoma cells (N-Ras controls; N-Ras Suv39h1 null; each genotype n=5) was 
isolated and cDNA was amplified using a p53 specific primer. Polymerase chain reaction was 
performed using a 5´- (exon 4) and a 3´-specific primer (exon 8) and sequenced in both directions 
(forward and reverse) using the respective primer. Representative sequencing analysis in 5´ direction 
of N-Ras controls (top) or Suv39h1 nulls (bottom); for 3´sequencing see appendix. 
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The observation that N-Ras Suv39h1 null animals die significantly earlier of an 
aggressive lymphoma compared to control mice suggests that those Suv39h1 
deficient animals might select for hematopoietic cells expressing extremely high 
levels of oncogenic Ras. This likely accelerates tumorigenesis as a response to 
enhanced Ras-signaling and provokes an early phenotype. 
To check for Ras expression levels, lymphoma cells of the respective genotypes 
were tested in an immunoblot analysis for their expression of Ras. For this, protein 
samples from whole cell lysates of low-passage lymphoma cells (N-Ras controls, 
Suv39h1 or p53 deficient) were separated by SDS-PAGE and probed with an anti-N-
Ras antibody. Data outlined in Figure 22 (left; top) showed that all samples showed a 
similar, but highly varying expression pattern of oncogenic N-Ras that is driven by the 
Eµ promoter. This variability is found throughout the genotypes.  
 
 
Figure 22: Ras levels, chromosomal instability, and Suv39h2 level in Suv39h1 null lymphoma. 
Left top: Western blot analysis of early passage lymphoma cells of the respective genotype. Whole 
cell lysates (80 µg) were loaded on a 15 % SDS-gel and the membrane was probed with an anti-N-
Ras (1:500) detecting human N-Ras (21 kDa) and tubulin (1:8000) of 50 kDa size as loading control 
(see also Figure 20; same membrane) Left bottom: RT-PCR for Suv39h2 from N-Ras lymphomas of 
the indicated genotypes, TATA-box-binding protein (TBP) as an internal control. Right: Chromosomal 
metaphase spreads of N-Ras controls, Suv39h1 null and p53 null early passage lymphoma cells (5 
per genotype). Colcemid arrested lymphoma cells were fixed, spread and stained with DAPI. 
Metaphases (12 of each lymphoma) were monitored and counted under the fluorescence microscope. 
 
These results potentially exclude that Suv39h1 defective or p53 null lymphomas 
select for high Ras-expressing cells during tumorigenesis, ruling out that accelerated 
lymphomagenesis is due to enhanced Ras signaling in mice with defects in the 
Suv39h1 or p53 locus.  
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Suv39h1 deficient cells do not show segregation defects  
 
Tumor formation is a multistep process that often requires the disruption of tumor 
suppressor proteins like p53. p53 is the gatekeeper of chromosomal integrity and 
since the gene is not mutated in Suv39h1 deficient lymphomas as shown in previous 
experiments it is rather unlikely that in those cells aneuploidy is the tumor driving 
force. However, it was shown that the Suv39h1/h2 knockout mouse quite frequently 
develops B cell lymphomas that are linked to chromosomal instability and to 
segregation defects (“butterfly chromosomes”)100. Despite the fact that in those 
animals lymphomas develop rather late, it might be assumed that in response to 
oncogenic Ras mice select for defects in the Suv39h2 locus that accordingly 
accelerate the formation of lymphomas caused by an instable karyotype. 
 
Metaphase spreads and Suv39h2 level 
In order to exclude that loss of Suv39h2 and subsequent chromosomal instability 
have an impact on Ras-driven lymphomagenesis, Suv39h2 status and chromosomal 
integrity were assessed in N-Ras lymphomas of the respective genotypes.  
 
To investigate Suv39h2 mRNA expression levels in Ras-induced lymphomas, RNA of 
low-passage lymphoma cells of wildtype, Suv39h1, or p53 null backgrounds was 
isolated and tested after gene-specific cDNA synthesis in a RT-polymerase chain 
reaction for the expression of Suv39h2. TATA-box-binding protein (TBP) served as 
an internal control.  
As the results of the RT-PCR unveil, all lymphomas used in this approach were 
positive for the Suv39h2 message detecting comparable housekeeping gene levels 
(TBP). This excludes a functional loss of Suv39h2 during N-Ras driven 
lymphomagenesis and the putative molecular basis for chromosomal instability 
(Figure 22; left bottom). 
 
However, since aneuploidy could be also driven by loss of the Suv39h1 protein 
alone, chromosomal integrity needs be evaluated in addition. To address this 
question, metaphase spreads of lymphoma cells (controls, Suv39h1- or p53-
deficient) were performed to detect numeric aberrations or segregation defect 
(“butterfly chromosomes”) in the manifest tumors. Therefore, low-passage lymphoma 
cells were arrested in the metaphase of the cell cycle using the spindle-checkpoint 
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toxin colcemid. After spreading the cell suspension on slides, metaphases were 
visualized with DAPI. To evaluate spreads at least 12 metaphases of each individual 
lymphoma were counted by fluorescence microscopy.  
“Butterfly” chromosomes or similar figures were never detected in more that 100 
metaphases of each sample tested throughout the genotypes. This already 
underlines that tumor formation is not related to a segregation defect (see 
representative pictures in Figure 22; right).  
Chromosome numbers only slightly varied in control and Suv39h1 null lymphomas 
from 40, whereas p53 null tumors tested for comparison showed increased 
chromosome numbers according to the p53´s function in chromosomal integrity and 
stability. The chromosome numbers were also confirmed by collaboration partners 
(Dr. Cornelia Rudolph - Medical School Hannover / Department of Cytogenetics).  
 
These data exclude that Suv39h1 deficiency provokes Ras-driven lymphomagenesis 
by segregation defects or polyploidy which was found to induce B cell lymphomas in 
the Suv39h1/2 knockout mice. 
 
 
3.4.2 Defects in cellular failsafe programs  
 
In the previous experiments it was shown that in response to oncogenic Ras loss of 
Suv39h1 leads to a rapid formation of aggressive lymphomas in vivo that is 
independent of segregation defects, selection for high Ras levels or the p53 status.  
It is likely that – as it was shown for p53 - loss of Suv39h1 accelerates Ras-driven 
tumorigenesis by disrupting the cellular failsafe machinery that normally prevents 
lymphoma formation. This is possible since mice with defects in the Suv39h1 locus 
display the similar time-to-death data and the same phenotypical features as p53 
animals. For this, it was investigated whether Suv39h1 null lymphomas are capable 
to respond to therapy-inducible failsafe programs like programmed cell death 







Defects in apoptosis: Loss of Suv39h1 produces apoptosis-competent Ras-
lymphomas 
 
In vitro growth and drug-responsibility of Ras-induced lymphomas 
The capability of a tumor cell population to expand in vitro and in vivo is 
characterized by a balance of growing and dying cells. Accordingly, a population that 
is apoptosis-incompetent grows faster, a characteristic of p53 deficient tumor cells.  
 
To address in vitro growth of the isolated lymphoma cells a growth curve analysis 
was performed. Therefore, well growing, low-passage lymphoma cells of the 
indicated genotypes were plated at identical cell numbers and viability was assessed 
by trypan blue exclusion over time (day 1-7). p53 null lymphoma cells were taken as 
control. Relative cell numbers were blotted against time (days).  
Data in Figure 23 (left) show that cells all grew in an exponential fashion irrespective 
of the genotypes and could be established in culture. Hereby, Suv39h1 null cells did 
not show a significant growth advantage compared to control cells while cell numbers 
increased approximately 10 fold after the indicated 7 days. Contrarily, results reveal 
that N-Ras p53 deficient lymphomas grow rapidly and faster compared to Suv39h1 
null or control cells (70 fold), underlining a putative apoptotic defect in Ras-driven p53 
null tumors, but not in control or Suv39h1 deficient lymphomas.   
 
 
Figure 23: Suv39h1 null lymphomas are apoptosis competent. Left: Growth curve analysis of 
control (n=5; black), Suv39h1 null (n=14; red) and p53 null (n=4; blue) lymphoma cells. Early passage 
lymphoma cells of the indicated genotypes were seeded at same cell numbers and viable cells were 
counted each day by trypan blue exclusion. Error bars denote standard deviation (plated in 
duplicates). Right: Drug-inducability and apoptosis-competence of cells as in (a). Short term 
cytotoxicity of control (black), Suv39h1 null (red) and p53 null (blue) cells using the indicated 
Adriamycin concentrations. After 24 hours incubation time viability was assessed by trypan blue 
counting. Error bars reflect standard deviation.  
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To prove the hypothesis whether an apoptotic defect contributes to the early death 
phenotype in Suv39h1 deficient lymphomas, cells were exposed to the anticancer 
drug Adriamycin (ADR), a topoisomerase-inhibitor and DNA-damaging agent that 
induces p53-dependent cell death. To evaluate this model, drug-inducible apoptosis 
was assessed by trypan blue exclusion in a short term cytotoxicity assay. 
As expected, lymphoma cells deficient for p53 did not respond to low dosages of 
Adriamycin and showed, even under high concentrations, almost no cell death after 
24 hours. Interestingly, Suv39h1 null lymphomas remained highly sensitive to the 
drug displaying increased apoptosis. This was also observed in N-Ras control 
lymphomas displaying manifest and increasing cell death after exposure with the 
anticancer drug (Figure 23; right). 
 
Those experiments clearly unveil that N-Ras driven Suv39h1 null tumors remain 
highly sensitive to drug-induced DNA-damage response and apoptosis competent 
like early death control lymphomas, whereas p53 null cells were incapable to trigger 
an apoptotic response. 
 
Defects in senescence: Loss of Suv39h1 produces senescence defective Ras-
lymphomas 
 
As previous results outline, Suv39h1 null lymphomas remain highly sensitive to DNA-
damaging drugs that cause a p53-depending cell death. This excludes a putative 
apoptotic defect that drives lymphomagenesis in response to oncogenic Ras.  
Hence, it is conceivable that premature senescence as another cellular failsafe 
program might be disrupted in Suv39h1 null cells promoting Ras-driven lymphoma 
formation. Accordingly, the capability of Suv39h1 deficient cells to trigger a 
senescence response will be addressed in the following section. 
There are several characteristics of a senescent cell population to uncover the 
senescent phenotype. One common feature and the gold standard to detect 
senescence is the upregulation of the lysosomal protein ß-galactosidase9. 
Upregulation can be visualized by an enzymatic reaction (senescence-associated ß-
galactosidase assay) resulting in a blue cytoplasmic staining. In addition, the terminal 
cell cycle arrest can be assessed by a growth curve analysis over time. Changes in 
cellular morphology and granularity, further indicators of cellular senescence, can be 
examined by the measurement of growth in a flow-cytometry approach (FSC/SSC). 
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Furthermore, senescence regulators that are upregulated can be evaluated in a 
Western blot analysis or by immunocytochemistry.  
 
Drug-induced senescence in Ras-driven lymphomas 
To assess whether Suv39h1 deficient lymphomas are still senescence competent 
and can undergo a terminal growth arrest, cells were treated again with Adriamycin. 
However, since apoptosis is the primary response to DNA damaging agents as 
shown in the setting before, cells need to be protected from programmed cell death. 
Therefore, low-passage lymphoma cells of all genotypes were retrovirally transduced 
with a murine MSCV-bcl2-puro construct and selected for puromycin resistant cells in 
order to obtain a 100% positive population expressing Bcl2. These apoptosis 
protected lymphomas were exposed to a 0.1 µg/ml dose of ADR for 5 days and 
tested for senescence after the indicated time points. Untreated cells served as a 
control. 
 
To assess the putative cell cycle arrest, ADR-treated cells and their respective 
controls were seeded (at identical cell numbers) on feeder plates (approximately 50% 
confluency). To determine growth capabilities, viable cells were counted every 24 
hours. After 3 days, an aliquot was taken to measure morphological changes in a 
flow cytometry approach (forward sidescatter analysis). Later (day 5), treated 
lymphomas and their untreated counterparts were cytospun for the senescence 
assay (SA-ß-galactosidase) and an immunocytochemistry approach. In addition, 
whole cell lysates were isolated to validate expression levels of the p16 and ARF 
proteins. 
The SA-ß-gal assay (outlined in Figure 24; top) unveils, as expected, in all untreated 
scenarios a SA-ß-gal negative and therefore non-senescent cell population. 
However, in N-Ras control lymphomas, nearly all cells turned blue (88%) after 5 days 
of Adriamycin treatment and forwardscatter/sidescatter analysis revealed an increase 
in granularity and size (inlays). Strikingly, Suv39h1 cells apparently lack a positive 
SA-ß-gal staining since almost no cells turned blue (9%) and retained size and 
granularity that is comparable to untreated cells. This observation suggests that Ras-
driven Suv39h1 deficient lymphomas are incapable of undergoing a senescent 
phenotype in response to DNA-damaging agents in vitro, whereas control cells 
senesce under the same treatment conditions. For comparison, p53 null cells - 
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known to inherit a senescence defect - did not respond to the drug (7% positive SA-
ß-gal; no change in size and granularity). 
Expectedly, growth curve analysis (Figure 24; bottom, left) of those lymphomas 
uncovered that all untreated cells (UT) grew exponentially with advantages for p53 
deficient lymphomas (see section before). In contrast, Adriamycin treated (ADR) N-
Ras controls remained viable and cell number did not increase after 5 days, 
indicative of a manifest growth arrest. Remarkably and in line with the SA-ß-
galactosidase staining, Suv39h1 null cells did not arrest in response to the drug and 
showed nearly identical cell numbers after 5 days with or without treatment. 
 
 
Figure 24: Suv39h1 null lymphomas are senescence defective. Top: Drug-inducible senescence 
in apoptosis-blocked control, Suv39h1 null and p53 null lymphoma cells. Low passage lymphoma cells 
were transduced retrovirally with a MSCV-bcl2-puro construct and treated after antibiotic-selection with 
a concentration of 0.1 µg/ml Adriamycin for five days. The respective untreated cell population was 
referred to as control. To assess the senescence phenotype cells were cytospun and stained for SA-ß-
galactosidase at day 5 (big pictures), percentage of senescent cells were outlined including standard 
deviations (n=3 each sample). Morphological changes (size/granularity) were determined at day3 in a 
forward scatter/side scatter (FSC/SSC) FACS analysis (inlays). Bottom: Growth analysis (n=4 each 
genotype) of Adriamycin treated cells (ADR) or the untreated control (UT) as in (a). Growth was 
assessed by trypan blue counting of the viable fraction (d0 / d5) in controls (black), Suv39h1 null (red) 
and p53 null (blue) lymphomas. Error bars note standard deviation. Immunoblot (right top) analysis of 
Bcl2-overexpressing cells as in (a) after 5 days with (ADR) or without Adriamycin treatment (UT). 
Whole cell lysates (80µg) were separated on a 15% SDS-gel and the membrane was probed with 
either an anti-p16 (1:500, recognizes murine p16 at 16 kDa) or an anti-ARF 1:500 (detects murine p19 
ARF at 19 kDa). α-tubulin (1:8000 at 50 kDa) as an internal loading control. Immunocytochemistry 
(right bottom) of cells after 5 days treatment with Adriamycin (ADR) or untreated cells for comparison 
(UT). Cytospins (right bottom) of apoptosis-blocked cells (as described above) were stained for their 





The p16 protein is a key player shown to be upregulated in Ras-induced senescence 
in vitro. To investigate p16 expression in the Adriamycin treated lymphomas, cells at 
day 5 were cytospun for an immunocytochemistry approach (Loddenkemper et al) 
and whole cell protein lysates were isolated to perform Western blot analysis. In 
parallel, also ARF levels were determined using the same test settings. 
Representative pictures are shown in Figure 24 (right, upper and lower pictures).  
Results of both experiments clearly show that after drug exposure p16 is 
overexpressed in the lymphomas independent of the genotype. Nevertheless, the 
ARF protein was only detectable in p53 deficient lymphoma samples after treatment 
and only slightly increases in Suv39h1 null cells after ADR. 
 
These data demonstrate that, in response to therapy, key regulators of the 
senescence machinery such as p16 are upregulated to induce a senescent 
phenotype. This seems to be irrespective of the genotype since p16 was found 
upregulated also in Suv39h1 and p53 deficient samples, assuming that the 
senescence machinery upstream of Suv39h1 is active and intact, but signals cannot 
be translated downstream. 
 
Taken together, drug-inducible senescence can be induced in Ras control lymphoma 
cells displaying all features of a senescent cell population - SA-ß-gal positivity, 
growth arrest, morphological changes as well as the upregulation of p16. Strikingly, 
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Suv39h1 deficient cells are incapable of senescing upon therapy; despite the fact 
that proteins such as p16 are upregulated.  
3.5 Molecular mechanism: Ras-induced senescence in 
lymphocytes and Suv39h1-dependency 
 
3.5.1 Ras and the function of Suv39h1 in primary lymphocytes 
 
Suv39h1 controls Ras-induced senescence by a H3K9-dependent mechanism 
 
As it was demonstrated in the previous experiments, Ras-induced lymphoma cells 
that arise in the absence of Suv39h1 are still apoptosis-competent, but fail to 
undergo premature senescence under therapy. However, since in the Eµ-N-Ras-
transgenic mouse model Ras is permanently overexpressed in the hematopoietic 
system, it is necessary to study the acute effect of oncogenic Ras on primary 
lymphocytes.  
 
Impact of oncogenic Ras in Suv39h1 proficient and deficient primary splenocytes 
To study this question, primary splenocytes were transduced with oncogenic Ras and 
assessed for a senescent phenotype. Splenocytes from either a non-transgenic 
wildtype or a Suv39h1 null mouse were isolated and retrovirally transduced with a 
selectable Ras vector (MSCV-H-ras-puro) and the empty vector control (MSCV-
puro), respectively. After puromycin selection, cells were seeded at identical cell 
numbers to determine growth capabilities and senescence-associated ß-
galactosidase after 6 days. 
The results are outlined in Figure 25 (bottom). Growth curve analysis (Figure 25 
middle) revealed that both empty vector transduced wildtype and Suv39h1 null 
splenocytes grew slowly, but comparably and increased in cell number about 2.5 
times after 6 days, while showing only a slight background staining for the 
senescence marker SA-ß-gal (around 5%; upper picture).  
Contrarily, H-Ras transduced wildtype splenocytes stopped proliferating while 
remaining viable and were nearly 80% positive for SA-ß-gal. However, in response to 
oncogenic Ras Suv39h1 cells still grew readily, retained viability and doubled after 
one week in culture, while showing only a moderate SA-ß-gal background (16%).  
 
 98
These data unveil that oncogenic Ras can induce a terminal cell cycle arrest in 
primary lymphocytes, while, remarkably, lymphocytes deficient for Suv39h1 are not 











































































Figure 25: Ras-induced senescence in primary lymphocytes is Suv39h1/H3K9me-dependent. 
Primary splenocytes isolated from Suv39h1 null and wildtype mice were pooled and retrovirally 
transduced with either a MSCV-H-RasV12-puro construct (Ras) or the empty vector only (vector). 
Right: After antibiotic selection cells were seeded at identical cell numbers and growth was 
determined after day 6. Growth of Suv39h1 wildtype (Suv39h1+/+, black) and Suv39h1 null (Suv39h1-
/-, red) splenocytes was assessed by trypan blue exclusion counting the viable cell fraction. Error bars 
denote standard deviations resulting from duplicates of two independent experiments. Left top and 
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bottom: Cytospin preparations of vector and Ras-transduced Suv39h1+/+ or Suv39h1-/- cells (see 
above) were plated in triplicates and stained for endogenous ß-galactosidase (b, means +/- standard 
deviation) and in an immunofluorescence assay (c) for trimethylated H3K9 (1:100, big pictures) and 
HP1-γ (1:100, inlays).  
The enzymatic function of Suv39h1 is characterized by the methylation of histone H3 
at lysine 9. From previous results it seems that Suv39h1 triggers a senescent 
phenotype in response to oncogenic Ras, however, it is not clear until now if this is 
accompanied with an increase in H3K9 methylation and HP1γ, a Suv39h1-linked 
protein associated with heterochromatin structures.  
To determine whether Ras-induced senescence depends on Suv39h1 function, Ras-
transduced splenocytes and their respective empty vector controls were tested for tri-
methylated histone H3 (H3K9me3) and HP1γ status, respectively. 
For this, splenocytes from the previous experimental setting were cytospun and 
tested in an immunofluorescence assay for both proteins. 
Results (Figure 25; lower picture) showed that in Ras-transduced, senescent wildtype 
splenocytes trimethylated histone H3 is clearly increased in the nucleus compared to 
normal empty vector transduced cells. The same was observed for the HP1γ protein 
that is obviously enriched in senescent wildtype cells after Ras-induction. 
Remarkably, cancellation of senescence by Suv39h1 deficiency showed neither an 
enrichment for trimethylated histone H3 nor HP1γ in response to oncogenic Ras.  
 
This potentially underlines that the functional loss of Suv39h1 promotes Ras-driven 
lymphomagenesis in vivo by cancelling senescence as putative failsafe machinery 

















Two major questions were addressed in this thesis. Firstly, does loss of the histone 
methyltransferase Suv39h1 have an impact on Ras-induced tumorigenesis in an in 
vivo mouse model. Secondly, if so, which underlying mechanism triggers the 
outcome of tumor formation, in particular, are cellular failsafe mechanisms like 
senescence controlled by Suv39h1 and do they counteract malignant transformation 




4.1 Relevance, controversial view, clinical aspect and perspectives 
 
Since decades it has been believed that cellular senescence is a telomere-
dependent phenomenon that occurs only in aging cells when a population looses the 
ability to divide6,7. However, studies of the late 90s have now demonstrated that 
senescence is not only restricted to cells “growing old”, but is also recruited after 
excessive mitogenic signaling, DNA damage as well as after chemotherapy or 
oxidative lesions13-16,107. This stress-inducible, intrinsic defense mechanism terminally 
locks the cell in a permanent arrest while it remains metabolically active, but 
insensitive to any growth signals. The tumor-suppressive potential of senescence in 
response to oncogenic stimuli was shown several years ago when permanently 
activated Ras provoked a terminal cell cycle arrest in vitro reminiscent of 
senescence.  
 
Disruption of regulators such as p16INK4a or p53 executed senescence and efficiently 
transform a cell as shown in several Ras-driven cell culture systems15. However, 
whether this failsafe program is relevant in vivo remained questionable. While there is 
clear evidence that defects in the apoptotic pathway contribute to cellular 
transformation in vitro and promote cancer formation in vivo, until now, premature 




Limitation of the model? 
 
A functional model to examine the role of Ras-induced senescence in vivo has not 
been addressed so far. Focussing on hematopoietic malignancies, in the present 
work, emphasis was based on senescence as a potential tumor suppressor 
mechanism to counteract Ras-provoked lymphoma formation. 
Comparable approaches exist to unveil the role of failsafe programs in oncogene-
driven lymphomagenesis. The Eµ-Myc transgenic mouse provides an excellent and 
already well established model to evaluate the impact of Myc-evoked apoptosis in 
lymphoma formation and treatment responses. Using this system, it was shown that 
disruption of tumor suppressors like p53 or INK4aArf in Eµ-Myc mice dramatically 
accelerates tumor formation and defects in these players significantly have an impact 
on treatment outcome106,109,110.   
Accordingly, we have chosen the Eµ-N-Ras transgenic mouse where oncogenic Ras 
is constitutively expressed in the hematopoietic compartment104. Despite the genetics 
of the N-Ras transgenic mouse model in which the oncogene is driven by the 
promoter of an immunoglobulin heavy chain enhancer (Eµ), mice did not succumb to 
B cell malignancies, but rather developed non-lymphoid sarcomas from macrophage 
origin, and only sporadically lymphoid tumors. However, those findings are well in line 
with already published data that N-Ras transgenic mice suffer from histiocytic 
sarcomas and quite reasonable since it was shown that the Eµ promoter indeed is 
active in other subpopulations of the hematopoietic compartment104. 
 
Markedly, defects in the Suv39h1 histone methyltransferase promote the formation of 
aggressive T lymphoblastic tumors in this model accompanied with significant 
differences in time-to-death latencies. This provides striking evidence that Ras-
induced lymphomagenesis is epigenetically regulated and suggests an important role 
for Suv39h1. Furthermore, this is supported by the finding that lymphomas in a 
Suv39h1 heterozygous background select against functional Suv39h1 expression 
during tumor formation. According to the Lyon Hypothesis111 this is likely since 
Suv39h1 is X-chromosomally linked and female mice per se inactivate one allele, 
generating a putative null scenario, therefore, it is easy to select for.  
These results indicate that in response to oncogenic Ras loss of Suv39h1 likely 




Suv39h1 is an Rb-bound enzyme102 catalyzing methylation of histone H3K9 that 
provides a binding site for heterochromatin proteins like HP1γ and locally provokes 
heterochromatin formation, also on E2F responsive S phase promoters103. Since 
methylated H3K9 was found as a characteristic feature of Rb-dependent 
heterochromatin foci in senescent cells, it was highly conceivable that Suv39h1 
silences E2F-responsive S phase genes to suppress cell proliferation in response to 
cellular oncogenes and contributes to a senescent cell cycle arrest30,93,102,112. Indeed, 
as shown in the present thesis, Suv39h1 regulates senescence in response to 
oncogenic Ras signaling in primary lymphocytes and provides an initial barrier during 
lymphomagenesis. 
 
Although the phenotype of the in vivo studies is quite impressive, the model itself can 
display a concern in this system. The Eµ-N-Ras transgenic mouse can be considered 
as rather not physiological since mutated N-Ras is overexpressed by an artificial 
promoter in the hematopoietic system. Hereby, Ras levels may not be comparable to 
levels in a physiological setting where endogenous Ras genes are mutated. 
This is an issue of debate since varying amounts of oncogenic Ras exhibit different 
effects on cells and are, in addition, highly dependent on the cell type or 
microenviromental factors113. It is broadly believed that moderate levels of the 
oncogene induce hyperproliferation, while only higher expression levels can induce 
an acute arrest. For instance, freshly isolated human fibroblasts start 
hyperproliferating in response to oncogenic Ras and do not exhibit a senescence 
phenotype; unlike fibroblast celllines in culture that were shown to arrest114. 
Accordingly, it seems that cells in culture are already sensitized to exogenous stimuli 
by repeated passaging and overexpression of p16, while freshly isolated fibroblasts 
likely would reflect the scenario in vivo. The observation that only supraphysiological 
Ras levels trigger a senescence response likely supports the idea that the tumor 
suppressive potential might only be a culture artefact or, as in the used mouse 
model, the consequence of excessive overexpression due to a strong promoter.  
However, together with the present thesis, hallmark studies published last year 
provide striking evidence that senescence indeed acts as a potential tumor 
suppressor mechanism in vivo to prevent cancer formation in human and mouse 
irrespective of the type of stimuli115,116.  
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Constitutive activation of the Ras-signaling pathway like K-RasG12V or mutated BRAF, 
a downstream effector of Ras, induces senescence in pre-malignant lesion like lung 
adenomas or naevi cell, the benign precursor cells of melanomas. The results unveil 
that in different model systems either endogenous mutations in K-RasG12V, titrated 
expression levels of exogenous BRAFV600E in vitro or BRAF mutations in patient 
samples can induce a senescence response. Together with our findings in the 
transgenic mouse model and the studies with overexpressed oncogenic H-RasV12G in 
vitro, it can no longer be insisted on the hypothesis that senescence is a level-
dependent culture artefact. Moreover, loss of the tumor suppressor PTEN in prostate 
glands of the mouse induces features of cellular senescence even without any 
modifications in the Ras-Raf-pathway117.  
These observations show that senescence is not only inducible by activated Ras-
signaling alone, but can also be triggered by regulators of the Akt-p53 axis. The 
papers unveil in a broad spectrum of pre-malignant entities cellular senescence as a 
tumor preventing program recruited in diverse tissues to counteract tumor formation.  
 
In addition, it was also reported quite recently that permanent activation of E2F in 
pituitary glands of the mouse causes a hyperproliferative stimulus and led, quite 
unexpectedly, to a terminal arrest. Rb-connected E2F is known to drive S-phase 
progression and initially, permanent activation was thought to transform a cell118. 
Interestingly, it was shown in this context that deregulated E2F instead causes a cell 
cycle arrest linked to Rb-dependent chromatin changes reminiscent of senescence. 
This is well in line with the outstanding hypothesis of a stress-responsive cellular 
failsafe machinery that can be activated in cells at risk for transformation. 
 
Most strikingly, we found evidence that in mice with endogenous Ras mutations 
lymphoma onset depends on the presence of the Suv39h1 histone methyltransferase 
(unpublished data, Schmitt lab), likely by controlling the same failsafe machinery as 
shown in the present thesis. Similar to the Eµ-N-Ras model, time-to-death data 
unveiled significant differences between control mice and Suv39h1 deficient animals 






Another issue that needs to be discussed in this model is the observation that 
lymphomas also form in Eµ-N-Ras control animals without any additional genetic 
defects. Even though control lymphomas form sporadically they need to acquire 
additional defects in Ras-induced signaling pathways or the cancellation of other 
tumor suppressing programs. However, a functional p53-pathway seems to be intact 
in these cells since lymphomas retain wildtype p53 transcript, show no aneuploidy 
and are sensitive towards exogenous p53-activating triggers such as ARF. 
Furthermore, Adriamycin can induce an apoptotic response and a senescent 
phenotype can be reiterated when cells are Bcl2-protected. Further investigation 
revealed that control lymphomas are unable to induce ARF protein levels in response 
to Adriamycin and also immunohistochemistry in situ showed only marginal 
expression of ARF, unlike in Suv39h1 and p53 deficient cells where ARF is 
detectable in situ. Preliminary data suggest that altered ARF, but not p16 expression 
provokes lymphoma growth in Eµ-N-Ras transgenic mice supporting the last findings 
(Braig and Schmitt, unpublished data). But whether ARF cancels Ras-induced 
senescence needs to be studied in more detail, likely by performing similar 
approaches described in the present thesis.  
 
Suv39h1 and its role in senescence: a functional bias? 
 
Recent data unveil that Ras induces cellular senescence to prevent improper 
proliferation and oncogenic transformation in vitro15. This includes Rb-related 
heterochromatin changes like methylation of histone H3K9 and the attraction of 
heterochromatin associated proteins like HP1 to repressive heterochromatin 
structures (SAHFs)30.  Indeed, in our system, primary lymphocytes respond to the 
acute introduction of oncogenic Ras with a terminal cell cycle arrest that is 
accompanied by the up regulation of senescent markers like SA-ß-galactosidase or 
increased HP1γ, which can be disrupted by loss of Suv39h1. These results 
underscore that senescence is an epigenetically controlled process mediating a 
terminal cell cycle arrest changing the local chromatin status. 
 
Suv39h1 is a histone methyltransferase that confers not only to constitutive 
heterochromatin formation on centromers, but also the silencing of euchromatic sites 
that locally repress transcriptional processes103. Thus, it might be able to induce 
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heterochromatin structures that directly or indirectly influence the repression of genes 
regulating an oncogene-dependent senescence response.  
Accordingly, it is possible that altered expression of senescence-proteins upstream of 
Suv39h1 confers lymphoma formation and not Suv39h1-dependent repression of 
E2F responsive promoters itself. This would rather imply the regulation of p16INK4a or 
a related protein controlling the Ras-Rb-senescence axis. However, screens for 
H3K9-silenced promoters in tumor cells unveiled several genes of which none is p16 
or another protein that controls the expression of a yet unknown senescence player. 
Studies on the INK4a promoter in senescent cells also showed no alteration in the 
acetylation status (H3K9) suggesting no change in methylation at the same histone 
residue. Indeed, in pre-senescent mouse embryonic fibroblasts (MEFs) oncogenic 
Ras was able to in induce p16 expression that does not depend on the Suv39h1 
status since p16 levels did not change in the absence or presence of Suv39h1 or 
even when Suv39h1 is overexpressed119. 
Of note, if Suv39h1 regulates the transcription of an unknown protein that controls 
senescence cannot be excluded. Studies including gene array experiments or global 
protein analysis (e.g. a proteomics approach) in Suv39h1 proficient vs. Suv39h1 
deficient scenarios should give a closer overview addressing potential target genes of 
Suv39h1 that might influence cell cycle progression, senescence or related 
mechanisms. 
 
Can histone demethylation mimic loss of Suv39h1? 
 
Until recently, no particular demethylase was discovered that potentially could 
remove the stable methyl mark on histone residues and could counter therefore 
Suv39h1 function. The observation that methylated lysines display the same half-life 
than histones supported the view that histone methylation may be a stable mark set 
on the nucleosome. Especially histone trimethylation, catalyzed by Suv39h1, appears 
to be relatively robust since trimethyl marks are stably propagated and do resist 
mammalian reprogramming during embryogenesis. 
 
Surprisingly, new data using more refined technologies showed that methylation of 
histones can be reduced. With the latest discovery of the lysine specific demethylase 
1 (LSD1) that acts specifically on mono- and dimethylated H3K4, the current view 
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about reverting histone methylation changed dramatically120. It was shown to convert 
H3K4me2 on active chromatin states and - when associated to another protein 
complex - even functionally different H3K9me2 marks on silenced chromatin 
regions121. In addition, a second demethylase (JHDM1), a JmjC domain containing 
protein, was found to exclusively demethylate H3K36me2122. 
Latest research on this field finally discovered JMJD2 (jumonji domain containing 2) 
family members, the first histone demethylases that are able to demethylate 
trimethylated lysines123. This is for particular interest since this could indeed convert 
the function of SU(VAR)3-9 proteins on H3K9 and counterpart its repressive function. 
Overexpression of such demethylases would, in principal, mimic loss of histone 
methyltransferases such as Suv39h1 and likely influence oncogene-induced tumor 
formation as well. It is clear that further work need to be investigated to uncover more 
details addressing the nature of reversing histone methylation, the selective interplay 
with HMTs and their function in cancer development. In this context it would be 
necessary to check for already known H3K9-related demethylases and their status in 
Suv39h1 deficient cells and particular their role in Ras-induced lymphomagenesis.   
However, the striking and reproducible phenotype observed in the tested mouse 
model, when Suv39h1 is genetically ablated, argues against such a mechanism.  
   
Relevance of epigenetic regulators in tumor formation and therapy 
 
A widely accepted hypothesis states that one alteration in a cell – like activation of 
Ras pathways, loss of PTEN function or permanent E2F signaling – is not sufficient 
to form a full-blown malignancy1,34. Disruption of additional key players that control 
cellular failsafe mechanisms is prerequisite for tumor formation. Indeed, p53 is one of 
the most frequent mutations in tumors; also the retinoblastoma protein is deregulated 
in a broad variety of cancers1.  
 
Contrarily, no distinct Suv39h1 modification, mutation or alteration was found in 
human entities so far that would emphasize its striking role protecting oncogene-
induced tumorigenesis. It would be an important new piece of data linking 
deregulated Suv39h1 function to a human neoplasia since another Rb-linked histone 
methyltransferase, Riz1, was found to be mutated in human cancers89,90. This 
suggests a comparable H3K9-mediated mechanism preventing tumorigenesis in 
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human, likely by regulating cellular senescence or other failsafe mechanisms. On the 
other hand, it might not be necessary to inactivate Suv39h1 itself since related 
proteins such as Rb are defective in human cancer that consequently would disrupt 
also Suv39h1 function and releases the pressure to inactivate Suv39h1. 
 
There is emerging evidence from different sides that histone modifications play a 
crucial role in cancer formation. Although a global view of disrupted histone 
modifications in cancer cells is still missing, plenty are already known to have an 
impact on malignant transformation. Mutations in genes coding for histone 
acetyltransferases are associated with lung or colon carcinomas, acute myeloid 
leukemia or epithelial cancer and HDAC1, a histone deacetylase, is overexpressed in 
prostate and gastric cancers77,124. In addition, aberrant expression of human histone 
methyltransferases like EZH2 is correlated with primary mammacarcinomas, 
Hodgkin’s lymphoma and prostate cancer125,126. Remarkably, those epigenetic 
alterations raise the possibility for therapeutic intervention.  
 
In contrast to genetic events, epigenetic changes like DNA methylation or histone 
modification can likely be reversed or interrupted by interfering with specific enzymes. 
In the last years, research has focussed on inhibitors targeting HDACs that were 
found to be overexpressed in a variety of human neoplasia. Combination treatments 
of HDAC inhibitors and DNA methylating agents are well tolerated in patients 
suffering from AML or the myelodisplastic syndrome and can reduce uncontrolled cell 
proliferation and apoptosis. However the anticancer effect remains obscure to date. 
Contrarily, we found that treatment of N-Ras transgenic mice with an HDAC inhibitor 
(Trichostatin A) and DNA demethylating agent (2-deoxy-5-azacytidine) accelerate 
tumor onset in those animals similar as to Suv39h1 deficiency119. This is well in line 
with the hypothesis stated in this thesis that Suv39h1 methylates histone H3K9 in 
Ras-induced senescent lymphocytes by silencing E2F-dependent genes. Inhibitors of 
histone deacetylases now potentially mimic loss of Suv39h1 in the Ras-model since 
hyperacetylated histones cannot be methylated in parallel, keeping transcription 
active on E2F-responsive promoters. This might prevent a senescent cell cycle 
arrest. HDAC inhibitors globally target histone acetylation; side effects on normal 
cells can not be excluded and whether this therapy activates a possible oncogene in 
another cell context still remains elusive. Accordingly, it seems that therapy based on 
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epigenetic alterations is highly cell-type dependent and restricted to specific tumor 
entities or stages.  
The increasing evidence for a direct link between histone methylation and cancer 
together with the recent discovery of functional histone demethylases now puts the 
focus more on histone methylation and will be of great impact for further therapeutic 
intervention.  
 
Restoring histone methylation in cancer cells could be an option to revert a malignant 
phenotype, likely by re-introducing a senescent growth arrest. This is quite 
reasonable since it was shown that pharmacological stabilization of p53 in PTEN-
deficient prostate cancer cells117 and inhibition of the ARF-repressor Tbx2 in 
melanoma cells directly restored cellular senescence preventing further malignant 
proliferation127,128.  
 
In close correlation with those findings, this thesis provides the first time evidence for 
a tight correlation between senescence as a histone-methylation governed program 
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5.2.1 Summary table of mice characters 
 
 
Table 2: Characteristics of terminal disease conditions in Eµ-N-Ras transgenic mice. Animals of 
the different genotypes were grouped according to time-do-death data (< 180 days early death; > 180 
days late death). Pathological and clinical characteristics are listed.  
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5.2.2 p53 sequencing analysis 
N-Ras controls 















































































































N-Ras Suv39h1 null 



















































































































































ARF     Alternate reading frame 
APS    Ammoniumoersulfate 
Bcl2     B cell lymphoma 2 
Bp    Base pair 
BSA     Bovine serum albumin 
CDK4    Cyclin-dependent kinase 4 
cDNA    Complementary DNA 
dH2O     Deionized water 
DAPI     4',6-diamidino-2-phenylindole 
DMEM   Dulbecco´s modified Eagle medium 
DMFO   N,N-dimethylformamide 
X-Gal    5-bromo-4-chloro-3-indolyl ß-D-galactoside 
DMSO   Dimethylsulfoxid 
DNA     Desoxyribonucleic acid 
DNase    Deoxyribonuclease 
DTT     Dithiothreitol 
E. coli   Escherichia coli 
EDTA    Ethylendiamintetraacetat = Titriplex III 
FCS     Fetal calf serum 
FITC     Fluoresceinisothiocyanat 
GFP     Green-fluorescent protein 
H3K9     Lysin 9 of Histone H3 
H3K9met3   Tri-methylated Lysine 9 of Histone H3 
HAT     Histone-Acetyltransferase 
HDAC    Histone-Deacetylase 
HEPES    N-2-hydroxyethylpiperazin-N'-2-ethanesulfonic acid 
HMT     Histonemethyltransferase 
HP1     Heterochromatin protein 1 
IF    Immunofluorescence 
IPT    Immunophenotyping 
IL-7     Interleukin-7 
IMDM    Iscove's modified Eagle's media 
INK4    Inhibitor of CDK4 
IRES    Internal ribosomal entry site 
kb     Kilobase 
LOH     Loss of heterozygosity 
MAP    Mitogen-activated protein (kinase) 
mRNA    Messenger-Ribonucleicacid 
MSCV    Murine stem cell virus 
mut    Mutated form of a gene or protein 
NP-40    Nonidet P-40 
PAGE    Polyacrylamid-gel electrophoresis 
PBS     Phosphate Buffered Saline 
PCR     Polymerase chain reaction 
PML     Promyelocytic leukemia 
PVDF    Poly vinylidene difluoride 
Rb     Retinoblastoma protein 
RNA     Ribonucleic acid 
RNase    Ribonuclease 
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rpm     Rotations per minute 
RT     Room temperature 
SA-β-Gal    Senescence-associated β-galactosidase 
SDS     Natriumdodecylsulfat 
Su(var)3-9   Suppressor of variegation 3-9 
TEMED    N,N,N´,N´-Tetramethylethylendiamin 
Tris     Tris(hydroxymethyl)aminomethane 
TritonX-100    Octylphenoldecaethylenglycolether 
TUNEL Terminal deoxynucleotidyl transferase mediated dUTP 
nick end labeling 
Tween 20   Polyoxyethylensorbitanmonolaurat 
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